[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1594
1. Vincent-Salomon A, Macgrogan G, Charaffe-Jauffret E, Jacquemier J, Arnould L: [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]. Bull Cancer; 2010 Mar;97(3):357-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas].
  • [Transliterated title] Identification en pratique clinique des carcinomes basal-like du sein : des carcinomes "triple zéro/BRCA1-like".
  • Basal-like carcinomas represent 10 to 15% of invasive breast carcinomas and have been identified from gene expression studies.
  • They share a high degree of similarity at the morphological, phenotypical and molecular level with BRCA1 tumors that justify the proposal of a different name such as "triple zero/BRCA1 like" carcinomas for sporadic basal-like carcinomas.
  • Indeed, the current "basal-like" name could suggest a myoepithelial cellular origin of such lesions.
  • Furthermore, tumors with such a basal-like immunophenotype constitute a heterogeneous group of tumors encompassing good prognosis tumors such as adenoid cystic and juvenile secretory carcinomas.
  • There is an urgent need for more specific therapies for basal-like/triple zero/BRCA1-like tumors.
  • Indeed, recent clinical trials with PARP inhibitors for basal-like/BRCA1 like tumors should improve the prognosis of these patients and are a direct benefit of a better understanding of the molecular biology of these tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Basal Cell / genetics. Gene Expression Profiling / methods. Genes, BRCA1
  • [MeSH-minor] BRCA1 Protein / genetics. BRCA1 Protein / metabolism. Biomarkers, Tumor. Female. Gene Silencing. Genes, p53 / genetics. Humans. Mutation / genetics. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Phenotype. Prognosis. Terminology as Topic


2. Minicucci EM, de Campos EB, Weber SA, Domingues MA, Ribeiro DA: Basal cell adenoma of the upper lip from minor salivary gland origin. Eur J Dent; 2008 Jul;2(3):213-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the upper lip from minor salivary gland origin.
  • Basal cell adenoma is an uncommon benign salivary gland neoplasm, presenting isomorphic basaloid cells with a prominent basal cell layer.
  • Taking into account that basal cell adenomas represent 1% of all salivary gland tumors, being the majority of cases in the parotid glands, the goal of this paper is to report a case of basal cell adenoma of the upper lip arising from minor salivary gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):533-6 [16053874.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):805-10 [15944978.001]
  • [Cites] Diagn Cytopathol. 1999 Jul;21(1):30-4 [10405805.001]
  • [Cites] J Oral Pathol Med. 1996 Jan;25(1):1-4 [8850349.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):251-9 [8776422.001]
  • [Cites] Semin Diagn Pathol. 1996 May;13(2):95-103 [8734415.001]
  • [Cites] J Craniomaxillofac Surg. 2000 Feb;28(1):56-61 [10851675.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):834-5 [1401223.001]
  • [Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]
  • [Cites] Acta Otolaryngol Suppl. 1969;263:155-9 [5269030.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec;57(6):271-6 [12612759.001]
  • [Cites] Oral Oncol. 2001 Jun;37(4):365-8 [11337269.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 May;31B(3):197-201 [7549761.001]
  • (PMID = 19212550.001).
  • [ISSN] 1305-7456
  • [Journal-full-title] European journal of dentistry
  • [ISO-abbreviation] Eur J Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC2635906
  • [Keywords] NOTNLM ; Basal cell adenoma / Immunohistochemistry / Minor salivary gland
  •  go-up   go-down


3. Elamin I, Zecević RD, Vojvodić D, Medenica L, Pavlović MD: Cytokine concentrations in basal cell carcinomas of different histological types and localization. Acta Dermatovenerol Alp Pannonica Adriat; 2008 Jun;17(2):55-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine concentrations in basal cell carcinomas of different histological types and localization.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common malignant skin tumor.
  • Cytokines as major mediators of the immune system have been shown to play an important role in biology of the neoplasm with the general predomination of Th2 cytokines, whereas IFN-?
  • OBJECTIVE: We were interested in comparing cytokine levels in BCC and cutaneous squamous cell tumors with BCC of different localization and histological subtypes.
  • MATERIAL AND METHODS: Explants from freshly excised BCC from 18 patients, and cutaneous squamous cell tumors (solar keratoses and Bowen's disease) from 9 patients were cultivated for 24 h.
  • RESULTS: Tissue explants of BCC contained significantly higher concentrations of IL-1beta, IL-4, IL-5, and IL-6 compared to those of squamous cell tumors.
  • CONCLUSIONS: Confirming the earlier findings that BCC is a tumor with a Th2 cytokine microenvironment, this study further shows that BCC situated on the head and neck produce even more of certain Th2 cytokines (IL-4 and IL-5) and TNF-alpha, a crucial immunosuppressive cytokine released upon UVB irradiation.
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. Cytokines / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / chemistry. Female. Humans. Interleukin-4 / analysis. Interleukin-5 / analysis. Male. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709290.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-5; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4
  •  go-up   go-down


Advertisement
4. Yu M, Zloty D, Cowan B, Shapiro J, Haegert A, Bell RH, Warshawski L, Carr N, McElwee KJ: Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J Invest Dermatol; 2008 Jul;128(7):1797-805
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles.
  • Basal-cell carcinoma (BCC), the most common neoplasm in humans, occurs in a variety of morphological presentations.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Expression Profiling. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Cyclooxygenase 2 / genetics. Disease Progression. Epithelium / metabolism. Female. Humans. MAP Kinase Signaling System. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Signal Transduction. Skin / metabolism. Wnt Proteins / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18200053.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


5. Prasad ML, Barbacioru CC, Rawal YB, Husein O, Wen P: Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Mod Pathol; 2008 Feb;21(2):105-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
  • We studied the expression of several myoepithelial and basal/stem cell markers (smooth muscle actin, calponin, smooth muscle myosin heavy chain, metallothionein, maspin, and p63) by immunohistochemistry in 23 adenoid cystic carcinoma and 24 polymorphous low-grade adenocarcinoma, to identify the most useful marker or combination of markers that may help their diagnoses.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Epithelial Cells / metabolism. Myocytes, Smooth Muscle / metabolism. Neoplasm Proteins / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Salivary Glands, Minor / metabolism. Salivary Glands, Minor / pathology. Treatment Outcome


6. Navarrete Isidoro O, Abad Fernández A, López Vime R, Jara Chinarro B, Juretschke Moragues MA: [Pulmonary metastasis of Basal cell carcinoma of the skin]. Arch Bronconeumol; 2005 Mar;41(3):169-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastasis of Basal cell carcinoma of the skin].
  • [Transliterated title] Metástasis pulmonares de un carcinoma basocelular cutáneo.
  • Basal cell carcinoma of the skin is a common neoplasm usually considered benign.
  • We report the case of a 41-year old man diagnosed with lung metastasis secondary to base cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Lung Neoplasms / secondary. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15766469.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Bohn AA, Wills T, Caplazi P: Basal cell tumor or cutaneous basilar epithelial neoplasm? Rethinking the cytologic diagnosis of basal cell tumors. Vet Clin Pathol; 2006 Dec;35(4):449-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell tumor or cutaneous basilar epithelial neoplasm? Rethinking the cytologic diagnosis of basal cell tumors.
  • The cytologic interpretation was malignant neoplasia with histiocytic inflammation.
  • Differentials included a carcinoma or, given the melanin pigment and variable morphology of the cells, possibly malignant melanoma.
  • Histologically, the tumor was diagnosed as a basal cell epithelioma.
  • Neoplasms that once were lumped into the broad histologic diagnosis of basal cell tumors have since been split into distinct entities, dependent on evidence of differentiation into epidermis, trichofollicular epithelium, or sweat or sebaceous glands.
  • Although histologic reclassification has resulted in removal of most of these entities from the original basal cell tumor category, a cytologic diagnosis of basal cell tumor continues to be used to represent the large, heterogeneous group of epidermal, trichofollicular, and adnexal skin tumors with basal cell characteristics.
  • The case in this report demonstrates the heterogeneity of neoplasms that may be diagnosed cytologically as basal cell tumors and supports the need for cytologic criteria and nomenclature that better reflect potential variation in tissue differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123253.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Komorski JA, Nienartowicz JM: [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis]. Otolaryngol Pol; 2009 Sep-Oct;63(5):442-7
Genetic Alliance. consumer health - Acinic Cell Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis].
  • [Transliterated title] Acinic cell carcinoma ślinianki przyusznej o nietypowym obrazie klinicznym i niekorzystnym przebiegu.
  • In the case of neck tumours, these are unfortunately late signs, but in patients with a primary neoplastic focus within the head and neck, neck tumour is often the first sign of the disease.
  • The authors describe a clinical case of neck tumour with initially unclear etiology.
  • The preoperative diagnostics including ultrasonography, thin-needle puncture, MRI, carotid angiography and videostroboscopy was significant for surgical treatment planning; yet it was the intraoperative clinical picture which indicated that the tumour derived from the inferior parotid pole.
  • The histopathological examination confirmed non-cornifying basal cell epithelioma only in the essential lesion with no metastases to lymph nodes and surrounding tissue margins free of infiltrates.
  • Two and a half years after the procedure, the patient presented with a tumour localized on the front thoracic wall and two rapidly enlarging tumours in the nape of the neck.
  • In the collected specimen of the tumour on the front thoracic wall, a diagnosis of acinic cell carcinoma was made.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery
  • [MeSH-minor] Aged. Head and Neck Neoplasms / secondary. Humans. Male. Neck Dissection / methods. Neoplasm Staging. Palliative Care. Prognosis. Thoracic Wall / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169911.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


9. Kilic E, Milde-Langosch K, Müller V, Wirtz R, Ihnen M: [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]. Pathologe; 2008 Nov;29 Suppl 2:347-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
  • [Transliterated title] Expression des "activated leukocyte cell adhesion molecule" im Mammakarzinom. Prädiktivität für das Ansprechen auf eine taxanfreie Chemotherapie.
  • AIMS: Activated leukocyte cell adhesion molecule (ALCAM) is a cell surface immunoglobulin expressed in breast cancer (BC) and is assumed to be implicated in tumourigenesis and tumour progression.
  • RESULTS: In the normal breast ALCAM is expressed in luminal and basal epithelial cells.
  • [MeSH-major] Antigens, CD / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / genetics. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Cell Adhesion Molecules, Neuronal / genetics. Fetal Proteins / genetics. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / genetics. Taxoids / administration & dosage
  • [MeSH-minor] Blotting, Western. Breast / pathology. Chemotherapy, Adjuvant. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Kaplan-Meier Estimate. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Predictive Value of Tests. Prognosis. RNA, Messenger / genetics. Receptors, Estrogen / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Oct 1;98(7):2134-42 [11568000.001]
  • [Cites] Med Sci Monit. 2006 Jul;12(7):BR245-56 [16810131.001]
  • [Cites] Eur J Cell Biol. 2002 Jun;81(6):313-21 [12113472.001]
  • [Cites] Onkologie. 2003 Oct;26(5):438-45 [14605459.001]
  • [Cites] Med Sci Monit. 2006 Aug;12(8):BR263-73 [16865058.001]
  • [Cites] Breast Cancer Res. 2004;6(5):R478-87 [15318930.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):769-74 [10702391.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1160-4 [15509676.001]
  • [Cites] J Pathol. 2005 Feb;205(3):359-76 [15532095.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 27;267(3):870-4 [10673383.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):533-8 [10502734.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):229-38 [11373098.001]
  • [Cites] Cell Mol Life Sci. 2007 Dec;64(24):3201-18 [17957337.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):403-9 [16484444.001]
  • [Cites] Oncology. 2005;68(4-6):462-70 [16024937.001]
  • (PMID = 18810438.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ALCAM protein, human; 0 / Antigens, CD; 0 / Cell Adhesion Molecules, Neuronal; 0 / Fetal Proteins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Taxoids
  •  go-up   go-down


10. McPherson T, Ogg G: Spontaneous resolution of basal cell carcinoma in naevoid basal cell carcinoma syndrome/Gorlin's syndrome. Clin Exp Dermatol; 2009 Dec;34(8):e884-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous resolution of basal cell carcinoma in naevoid basal cell carcinoma syndrome/Gorlin's syndrome.
  • We describe a 10-year-old patient with naevoid basal cell carcinoma syndrome (NBCCS) which was diagnosed when she was 3 years old.
  • She has developed multiple basal cell carcinomas (BCCs) over this time, in particular on her face and trunk.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Child. Female. Humans. Neoplasm Regression, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055856.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Puri PK, Galan A, Glusac EJ, Cowper SE: Metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm. J Cutan Pathol; 2008 Jan;35(1):54-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm.
  • OBJECTIVE: Metastatic cutaneous neoplasms may be difficult to differentiate from primary cutaneous neoplasms.
  • Herein, we report an unusual case of metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm.
  • METHODS: A 53-year-old male man presented with a neoplasm on the vertex of the scalp, clinically resembling a pigmented basal cell carcinoma.
  • After acquiring additional clinical information and the complete excision of the neoplasm, further immunohistochemical stains supported the diagnosis a metastatic carcinoid tumor.
  • CONCLUSION: To our knowledge, this is the first case of metastatic carcinoid tumor reported that has mimicked a poroid neoplasm.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Apocrine Glands / pathology. Carcinoid Tumor / diagnosis. Skin Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095995.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Rütten A, Hantschke M, Angulo J, Requena L: Clear-cell dermal duct tumour: another distinctive, previously underrecognized cutaneous adnexal neoplasm. Histopathology; 2007 Dec;51(6):805-13
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell dermal duct tumour: another distinctive, previously underrecognized cutaneous adnexal neoplasm.
  • AIMS: To describe 13 examples of clear cell dermal duct tumour, a neoplasm previously underrecognized in the literature.
  • METHODS AND RESULTS: Thirteen examples of a neoplasm that we have named clear-cell dermal duct tumour were studied histopathologically and immunohistochemically.
  • Histopathologically, all lesions consisted of mostly dermal neoplasms mainly composed of multiple solid aggregations of clear cells involving the dermis.
  • Although the neoplasms were mostly solid, ductal structures were identified in all cases.
  • Epithelial membrane antigen, carcinoembryonic antigen and glial cystic disease fibrillary protein 15 decorated the ductal structures, but neoplastic cells were negative.
  • In contrast to some other clear cell neoplasms of the skin, which may be associated with diabetes mellitus, none of our cases of clear cell dermal duct tumour developed in a diabetic patient.
  • CONCLUSIONS: We consider these neoplasms to be clear cell dermal duct tumours for the following reasons: (i) the neoplasms were mostly composed of multiple solid aggregations of epithelial clear cells;.
  • (iv) small areas of necrosis en masse were seen in some neoplastic aggregations; and (v) the stroma of the neoplasm was scant.
  • [MeSH-major] Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Sweat Gland Neoplasms / metabolism. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Bowen's Disease / pathology. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nevus / pathology. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18042069.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Chadha V, Wright M: Small margin excision of periocular basal cell carcinomas. Br J Ophthalmol; 2009 Jun;93(6):803-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small margin excision of periocular basal cell carcinomas.
  • AIMS: To analyse the outcome of small margin (up to 2 mm) excision of primary clinically well-defined periocular basal cell carcinomas (BCCs).
  • All patients underwent excision of the tumour with maximum margins of 2 mm.
  • In the absence of availability of Mohs surgery, well-demarcated nodular basal cell carcinomas can be safely excised using smaller margins than conventionally practised.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Ophthalmol. 2010 Aug;94(8):1114 [20530178.001]
  • (PMID = 19304655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Chuprov IN: [Immunomorphological features of cutaneous basal-cell carcinoma]. Vopr Onkol; 2008;54(6):715-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunomorphological features of cutaneous basal-cell carcinoma].
  • An immunohistochemical study of p53, Ki-67, bcl-2, CK-8 and collagen IV was conducted in 47 basal-cell carcinomas (BCC) to ascertain their prognostic value.
  • CK-8 expression did not vary significantly within the 67.21-71.39% of tumor cells as far as different histotopographic patterns are concerned.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Skin Neoplasms / chemistry. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Basement Membrane / chemistry. Basement Membrane / pathology. Collagen Type IV / analysis. Female. Humans. Immunohistochemistry. Keratin-8 / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241845.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Keratin-8; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


15. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H: Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol; 2007 Dec;157 Suppl 2:47-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and aetiology of basal cell carcinoma.
  • Basal cell carcinoma (BCC) is a malignant epithelial neoplasm of the skin preferentially affecting male caucasians and is rarely observed in patients with more intense skin pigmentation.
  • Epidemiological data indicate that the overall incidence is increasing worldwide significantly by about 3-10% per annum.(1-3) Based on the increasing incidence of this usually not life-threatening tumour BCC appears to develop into a growing public health problem.
  • This review elucidates the risk factors for the development and for the progression of BCC leading to an improved understanding of this tumour.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Disease Progression. Humans. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067632.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 66
  •  go-up   go-down


16. Grønbaek K, Guldberg P: [Acquired mutations--basic cancer biology]. Ugeskr Laeger; 2006 Jun 12;168(24):2335-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Erhvervede mutationer--basal cancerbiologi.
  • It is now well-established that cancer is a genetic disease, although in most cases not inherited.
  • A sporadic cancer develops when a somatic cell acquires specific growth advantages through successive accumulation of changes in cancer genes, including oncogenes, tumor suppressor genes and stability genes.
  • Herein, we give a brief overview of the basic genetic changes in cancer and discuss how specific gene alterations may contribute to the development of malignant melanoma.
  • [MeSH-major] Mutation / genetics. Neoplasms / genetics
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Melanoma / genetics. Models, Genetic. Neoplasm Metastasis / genetics. Oncogenes / genetics. Skin Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16822414.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


17. Prabhakaran VC, Gupta A, Huilgol SC, Selva D: Basal cell carcinoma of the eyelids. Compr Ophthalmol Update; 2007 Jan-Feb;8(1):1-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelids.
  • Basal cell carcinoma is the most common malignancy in humans, and it is also the most frequent periocular malignancy.
  • Although a slow-growing tumor, it can lead to significant morbidity in the periocular region as a result of orbital invasion.
  • Management needs to be individualized, taking into account patient factors, tumor characteristics, and histological subtype.
  • In this review, we discuss the risk factors, pathology, molecular biology, clinical features, and management of eyelid basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms
  • [MeSH-minor] Australia / epidemiology. Combined Modality Therapy. Diagnosis, Differential. Humans. Incidence. Neoplasm Invasiveness. Orbital Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Compr Ophthalmol Update. 2007 Jan-Feb;8(1):15-6 [17394755.001]
  • (PMID = 17394754.001).
  • [ISSN] 1527-7313
  • [Journal-full-title] Comprehensive ophthalmology update
  • [ISO-abbreviation] Compr Ophthalmol Update
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  •  go-up   go-down


18. Saetta AA, Stamatelli A, Karlou M, Michalopoulos NV, Patsouris E, Aroni K: Mutations of microsatellite instability target genes in sporadic basal cell carcinomas. Pathol Res Pract; 2007;203(12):849-55
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of microsatellite instability target genes in sporadic basal cell carcinomas.
  • The aim of our study was to investigate the prevalence of mutations in the above 4 MSI target genes in correlation with the MSI status of 75 basal cell carcinomas (BCCs), including aggressive-growth BCCs and cases with perineural invasion.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. DNA-Binding Proteins / metabolism. Frameshift Mutation. Microsatellite Instability. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Humans. Male. Polymorphism, Single-Stranded Conformational

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950544.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MSH3 protein, human; 0 / Receptors, Transforming Growth Factor beta; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


19. Schulte KW, Lippold A, Auras C, Bramkamp G, Breitkopf C, Elsmann HJ, Habenicht EM, Jasnoch V, Müller-Pannes H, Rupprecht R, Suter L: Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol; 2005 Dec;53(6):993-1001
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas.
  • BACKGROUND: We have used a schedule for soft x-ray therapy of epithelial malignancies that takes into account the clinically diagnosed tumor involution under treatment.
  • METHODS: Patients with 1267 consecutively irradiated (1988-1992) basal cell and squamous cell carcinomas were followed up (average 77 months).
  • RESULTS: The recurrence rate (5.1%) was related to tumor size and thickness and to the time-dose-fractionation factor.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy Dosage. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310060.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Kuroda N, Fujishima N, Inoue K, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH: Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas. Med Mol Morphol; 2008 Jun;41(2):117-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas.
  • Some investigators have previously suggested that basal-like carcinoma may consist of components of invasive ductal carcinoma, not otherwise specified, metaplastic carcinoma, and medullary carcinoma.
  • We report here two cases of breast carcinoma showing basal cell/myoepithelial differentiation.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 May 1;66(9):4636-44 [16651414.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Oncology. 2005;69(6):478-85 [16410686.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Cancer Sci. 2005 Jan;96(1):48-53 [15649255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1217-26 [16938528.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):347-53 [15725803.001]
  • [Cites] Histopathology. 2006 Jul;49(1):10-21 [16842242.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R61 [17069663.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4003-11 [15930334.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):197-202 [10680887.001]
  • [Cites] Histopathology. 2005 Nov;47(5):458-66 [16241993.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 [14519755.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1506-11 [16941011.001]
  • [Cites] Histopathology. 2006 Jul;49(1):22-34 [16842243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • (PMID = 18592167.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Koutlas IG, Koch CA, Vickers RA, Brouwers FM, Vortmeyer AO: An unusual ostensible example of intraoral basal cell carcinoma. J Cutan Pathol; 2009 Apr;36(4):464-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual ostensible example of intraoral basal cell carcinoma.
  • An example of oral basal cell carcinoma is presented originating on the posterior mandibular mucosa and gingiva of a 67-year-old female.
  • Tissue samples of the tumor were evaluated with monoclonal antibody Ber-EP4 and were compared with examples of oral mucosa, skin, oral and cutaneous squamous cell carcinoma, peripheral ameloblastoma, ameloblastoma and cutaneous basal cell carcinoma (BCC).
  • Only neoplastic basal cells showed positive immunohistochemical staining.
  • These observations support the inclusion of BCC in the differential diagnosis of appropriate oral mucosal neoplasms.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mouth Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Loss of Heterozygosity. Receptors, Cell Surface / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278434.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Cell Surface; 0 / human epithelial antigen-125; 0 / patched receptors
  •  go-up   go-down


22. Lee S, Cnaan RB, Paramanathan N, Davies M, Benger R, Ghabrial R: Subconjunctival "ring" recurrence of Basal cell carcinoma of the globe. Ophthal Plast Reconstr Surg; 2010 Mar-Apr;26(2):117-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subconjunctival "ring" recurrence of Basal cell carcinoma of the globe.
  • Basal cell carcinoma is the most common indication for orbital exenteration.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305512.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Tonini G, Rosini R, Teppa A, Aulenti V, Kalantary F, Tosana M, Bianchi D, Zorzi F: [Adenoid cystic/basal cell carcinoma of the prostate:case report]. Urologia; 2008 Oct-Dec;75(4):245-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic/basal cell carcinoma of the prostate:case report].
  • The adenoid cystic/basal cell carcinoma of the prostate is a rare tumor with distinctive histopathologic features.
  • There are quite few publications in the literature concerning the diagnosis, treatment, and prognosis of this neoplasm.
  • METHODS. A 71-year-old man had an increased PSA value (5.11 ng/dL); the prostatic biopsy examination was positive for adenoid cystic/basal cell carcinoma.
  • The histology examination showed an acinar conventional carcinoma and adenoid cystic/basal cell carcinoma.
  • CONCLUSIONS. Various histologic and immunohistochemical features are helpful in recognizing the adenoid cystic/basal cell carcinoma of the prostate.
  • This tumor has a biological potential that can result in metastases in some cases; the current treatment consists primarily in the surgical resection.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086341.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Stafanous S: Five-year cycle of basal cell carcinoma management re-audit. Orbit; 2009;28(4):264-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year cycle of basal cell carcinoma management re-audit.
  • AIM: To complete a 5-year audit cycle for all malignant lid tumours treated by one consultant (Stafanous) and re-audit the first work done in 2000 and 2001/2002.
  • The main aim was to find out the recurrence rate and presence of new lesions in 5-years' follow-up and determine whether it is safe to discharge patients after histological clearance and satisfactory reconstruction outcome rather than 5 years' follow-up.
  • RESULTS: Out of 112 cases identified, 104 were Basal Cell Carcinoma (BCC), 4 Squamous Cell Carcinoma (SCC), 3 Sebaceous Gland Carcinoma (SGC) and 1 Malignant Melanoma (MM).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Medical Audit. Melanoma / surgery. Middle Aged. Mohs Surgery. Neoplasm Recurrence, Local. Postoperative Complications. Reconstructive Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839887.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Boswell JS, Flam MS, Tashjian DN, Tschang TP: Basal cell carcinoma metastatic to cervical lymph nodes and lungs. Dermatol Online J; 2006;12(6):9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
  • Metastatic basal cell carcinoma (MBCC) of the skin is rare in occurrence and may initially elude proper diagnosis and management.
  • In addition to the more commonly metastasizing carcinomas, metastases from a cutaneous basal cell carcinoma primary tumor should be considered when evaluating cervical lymph node metastases of an uncertain head and neck primary.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Carcinoma, Papillary / diagnosis. Diagnostic Errors. Head and Neck Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary. Radiotherapy. Seminoma. Skin Neoplasms / surgery. Taxoids / administration & dosage. Testicular Neoplasms. Thyroidectomy. Unnecessary Procedures

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083889.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


26. Ting PT, Kasper R, Arlette JP: Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg; 2005 Jan;9(1):10-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: report of two cases and literature review.
  • BACKGROUND: Metastatic basal cell carcinoma (MBCC) is defined as primary cutaneous basal cell carcinoma (BCC) that spreads to distant sites as histologically similar metastatic deposits of BCC.
  • Perineural space invasion may be an indicator of aggressive disease.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Facial Neoplasms / pathology. Facial Neoplasms / therapy
  • [MeSH-minor] Fatal Outcome. Female. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Metastasis. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208438.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


27. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404670.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


28. Chew R: Destruction of the orbit and globe by recurrence of basal cell carcinoma. Optometry; 2007 Jul;78(7):344-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Destruction of the orbit and globe by recurrence of basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common skin malignancy and represents 90% of eyelid malignancies.
  • CASE REPORT: The patient described in this case report had basal cell carcinoma of the upper right lid 4 to 5 years prior to examination.
  • He had extensive surgery to remove the tumor and subsequent skin grafting.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Orbit / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601572.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Sun J, Gui X, He J, Liu HM, Yu HY, Xia CY, Xu Y: [The relationship between infestation of Demodex folliculorum and epidermal neoplasm on face]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2005 Dec 30;23(6):428-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The relationship between infestation of Demodex folliculorum and epidermal neoplasm on face].
  • OBJECTIVE: To discuss the relationship between infestation of Demodex folliculorum and facial epidermal neoplasm.
  • METHODS: A retrospective analysis was made with the pathological data of 153 cases collected in the recent four years on facial basal cell carcinoma, squamous cell carcinoma, seborrheic keratosis and trichilemmoma.
  • The infection rate of Demodex folliculorum in the four types of neoplasm was evaluated and the relationship between the infection rate and the location of neoplasm and age was analyzed by V2 test.
  • RESULTS: There was a significant difference in the infestation rate of Demodex folliculorum in the four types of epidermal neoplasm(P < 0.05), with the highest rate in basal cell carcinoma(56%), compared with seborrheic keratosis (21%), trichilemmoma (20%), and squamous cell carcinoma (14%).
  • The infestation rate of Demodex folliculorum was significantly different in variant locations of epidermal neoplasm (P < 0.05).
  • The highest infestation rate was in cases of nasal neoplasm (71%), compared with other parts.
  • In addition, among twelve cases of Demodex folliculorum positive nasal neoplasm, nine were basal cell carcinoma; ten of thirty-six basal cell carcinoma occurred on nose.
  • CONCLUSION: The highest infestation rate of Demodex folliculorum was in cases of nasal epidermal neoplasm compared with other locations, and the cases of basal cell carcinoma showed the highest infestation rate among the four types of neoplasm.
  • [MeSH-major] Facial Neoplasms / etiology. Mite Infestations / complications. Skin Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566213.001).
  • [ISSN] 1000-7423
  • [Journal-full-title] Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases
  • [ISO-abbreviation] Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Pham TT, Selim MA, Burchette JL Jr, Madden J, Turner J, Herman C: CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol; 2006 Feb;33(2):123-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in trichoepithelioma and basal cell carcinoma.
  • BACKGROUND: Trichoepithelioma (TE) is a benign neoplasm that shares both clinical and histologic features with basal cell carcinoma (BCC).
  • However, it is important to distinguish these neoplasms.
  • Cases were analyzed for pattern of CD10 expression by tumor cells and surrounding stroma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Neoplasms, Basal Cell / metabolism. Neprilysin / metabolism. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420307.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


31. McGregor DH, Cherian R, Romanas MM, Ulusarac O, Mathur SC, Feldman MM: Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma. Ann Clin Lab Sci; 2008;38(2):157-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma.
  • We report 2 cases of collision tumors involving amelanotic malignant melanoma of the back.
  • One patient is a 79-yr-old male with an 8.7 x 5.5 x 4.5 cm polypoid lesion that on shave biopsy was diagnosed as basal cell carcinoma.
  • Subsequent excision showed that the lesion was largely composed of amelanotic melanoma underlying a relatively small and thin basal cell carcinoma, and this probably would have been demonstrated in a punch (rather than shave) biopsy.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Histiocytoma, Benign Fibrous / diagnosis. Melanoma, Amelanotic / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469362.001).
  • [ISSN] 1550-8080
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Kump E, Ji J, Wernli M, Häusermann P, Erb P: Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis. Oncogene; 2008 Jun 19;27(27):3856-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis.
  • Mutations in the Hedgehog signaling pathway is responsible for the formation of various cancers, including some forms of basal cell carcinoma (BCC).
  • The direct functional connection between Gli2 and cFlip was not only demonstrated in a keratinocytic cell line but also in BCC tissue.
  • As cFlip and Bcl-2 are highly expressed in BCCs, as a consequence of high Gli2 expression, this may explain the marked resistance of the tumor to the extrinsic and intrinsic apoptotic pathway.
  • We could now demonstrate that Gli2 gene silencing in BCC tissues made the tumor sensitive to TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated cell death by downregulating cFlip.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Basal Cell / pathology. Gene Expression Regulation, Neoplastic. Kruppel-Like Transcription Factors / genetics. Nuclear Proteins / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / physiology
  • [MeSH-minor] Carboxylic Ester Hydrolases / physiology. Cell Death. Cell Line. Cell Line, Tumor. Down-Regulation. Drug Resistance, Neoplasm. Gene Silencing. Humans. Intracellular Signaling Peptides and Proteins. Keratinocytes / physiology. Mitochondrial Proteins / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264131.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI2 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Mitochondrial Proteins; 0 / Nuclear Proteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; EC 3.1.1.- / Carboxylic Ester Hydrolases; EC 3.1.1.29 / PTH2 protein, human
  •  go-up   go-down


33. Schulz T, Proske S, Hartschuh W, Kurzen H, Paul E, Wünsch PH: High-grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal neoplasm often showing metastatic spread. Am J Dermatopathol; 2005 Feb;27(1):9-16
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal neoplasm often showing metastatic spread.
  • It has been debated whether malignant transformation of trichoblastoma occurs.
  • The concept was recently forwarded that basal cell carcinoma is as a malignant neoplasm of follicular germinative cells and should be named trichoblastic carcinoma to show its relationship to trichoblastoma.
  • Almost all basal cell carcinomas are low-grade malignant neoplasms and develop metastases only very rarely, and if so, only after very long duration and untreated growth.
  • Only rare basal cell carcinomas arise in trichoblastomas.
  • Our cases emphasize that high-grade trichoblastic carcinoma develops via malignant transformation of trichoblastoma, and is very rare.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Carcinoma, Skin Appendage / secondary. Hair Diseases / pathology. Hair Follicle / pathology. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Female. Humans. Immunoenzyme Techniques. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677970.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Kiyici H, Bilezikçi B, Ozen O, Demirhan B: Immunohistochemical FHIT expression still exists in early lesions of basal cell carcinoma. Pathol Res Pract; 2010 Jul 15;206(7):445-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical FHIT expression still exists in early lesions of basal cell carcinoma.
  • In this study, we evaluated the expression of Fragile Histidine Triad (FHIT) in basal cell carcinoma (BCC).
  • As a second finding, there was no correlation between the intensity of FHIT staining and Ki-67 labeling index.
  • As a third finding, there was no difference in Ki-67 labeling index between early lesions of BCC and non-neoplastic epidermis.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Carcinoma, Basal Cell / metabolism. Neoplasm Proteins / biosynthesis. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20399571.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


35. Kawata R, Yoshimura K, Lee K, Araki M, Takenaka H, Tsuji M: Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor. Eur Arch Otorhinolaryngol; 2010 May;267(5):779-83
Genetic Alliance. consumer health - Warthin's tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor.
  • The aim of this study is to investigate the clinical and pathological characteristics of basal cell adenoma (BCA) and to compare the diagnosis/treatment of BCA with those of Warthin's tumor (WT) and pleomorphic adenoma (PA).
  • Among 192 patients with benign tumors of the parotid gland who underwent surgery, 9 had BCA.
  • All of these tumors showed a benign pattern on computed tomography and magnetic resonance imaging.
  • Considering the gender difference, tumor site, and age, it is necessary to differentiate BCA from PA rather than from WT.
  • BCA is the third most common of the benign parotid tumors, following WT and PA, although its incidence is low.
  • When PA and WT are ruled out by FNAB after a tentative diagnosis of benign tumor has been based on imaging findings, BCA should be considered.
  • [MeSH-major] Adenolymphoma / pathology. Adenoma / pathology. Adenoma, Pleomorphic / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2007 Feb;35(2):85-90 [17230571.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • [Cites] Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1967;189(3):302-16 [5595712.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):260-4 [15468947.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):736-45 [6284339.001]
  • [Cites] Br J Radiol. 2005 Jul;78(931):642-5 [15961849.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar 01;11(2):E206-9 [16505803.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]
  • (PMID = 19908055.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Kunte C, Konz B: [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt; 2007 May;58(5):419-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].
  • The incidence of the most common tumors of the skin, basal cell carcinoma and squamous cell carcinoma, has risen rapidly in recent years.
  • They must be able to develop therapeutic strategies adapted to the tumor and the patient.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Prognosis. Radiotherapy, Adjuvant. Skin / pathology. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] Hautarzt. 2005 May;56(5):430-40 [15815888.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] J Dermatol Surg Oncol. 1994 May;20(5):350 [8176049.001]
  • [Cites] Recent Results Cancer Res. 2002;160:219-24 [12079216.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):91-5 [17190625.001]
  • [Cites] Br J Dermatol. 2006 Jun;154(6):1202-3 [16704658.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30 [16922939.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2 [16626324.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Jul;17(7):574-8 [1860987.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Hautarzt. 1975 Dec;26(12):647-50 [1213885.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 May;4(5):441-3 [16686614.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72 [12459530.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Recent Results Cancer Res. 2002;160:240-5 [12079219.001]
  • (PMID = 17443305.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


37. Chen GS, Yu HS, Lan CC, Chow KC, Lin TY, Kok LF, Lu MP, Liu CH, Wu MT: CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol; 2006 May;154(5):910-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma.
  • BACKGROUND: Chemokines and their receptors, well known for their ability to attract leucocytes, also play important roles for tumour progression.
  • OBJECTIVES: To investigate the possible involvement of chemokine receptors in the pathogenesis of cutaneous basal cell carcinoma (BCC).
  • METHODS: We performed an expression analysis of chemokine receptors using a well-characterized human BCC cell line.
  • Upon the finding of CXCR4 expression by BCC, retroviral transduction of BCC cells with the CXCR4 gene was employed to address its functional significance for BCC in vitro and in vivo.
  • RESULTS: We found expression of the CXC chemokine receptor CXCR4 by a human cell line and a subset of tissue samples from BCC, especially in noduloulcerative and sclerosing types.
  • Moreover, xenograft tumour transplants produced by injection of CXCR4-BCC yielded significant tumour progression in nude mice, whereas additional serial injections of CXCR4-blocking peptides resulted in tumour regression.
  • CONCLUSIONS: CXCR4 expression may play a critical role in tumour progression and angiogenesis of certain subtypes of BCC with more aggressive nature, and functional blockade of CXCR4 could be a potential therapeutic strategy for these tumours.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Cell Transformation, Neoplastic / metabolism. Neovascularization, Pathologic / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Apoptosis / radiation effects. Cell Proliferation. Chemokine CXCL12. Chemokines, CXC / physiology. Disease Progression. Female. Humans. Mice. Mice, Nude. Neoplasm Proteins / metabolism. Neoplasm Transplantation. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction. Transduction, Genetic. Transplantation, Heterologous. Tumor Cells, Cultured. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634895.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Neoplasm Proteins; 0 / Receptors, CXCR4
  •  go-up   go-down


38. Ramachandran S, Rajaratnam R, Smith AG, Lear JT, Strange RC: Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. J Am Acad Dermatol; 2009 Aug;61(2):247-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma.
  • BACKGROUND: The rate of development of further basal cell carcinoma (BCC) after first presentation is highly variable.
  • OBJECTIVE: We assessed the risks of developing a subsequent BCC in patients who developed a BCC and a squamous cell carcinoma (SCC) and compared them with patients who developed a BCC only.
  • METHODS: In all, 1040 patients who developed BCC only were compared with 140 patients who developed BCC and SCC to see whether the latter group included a high proportion of risk phenotypes (eg, male sex and fair skin).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Multiple Primary / epidemiology
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Cohort Studies. Confidence Intervals. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Probability. Prognosis. Risk Assessment. Sex Distribution

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19481292.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Leibovitch I, McNab A, Sullivan T, Davis G, Selva D: Orbital invasion by periocular basal cell carcinoma. Ophthalmology; 2005 Apr;112(4):717-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital invasion by periocular basal cell carcinoma.
  • OBJECTIVES: To present a large series of patients with orbital invasion by periocular basal cell carcinoma (BCC).
  • MAIN OUTCOME MEASURES: Patients' demographics, clinical presentation, histologic subtypes, treatment modalities, recurrence rate, and tumor-related death.
  • Only 1 patient (1.6%) died from tumor-related causes.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Peripheral Nervous System Neoplasms / radiotherapy. Peripheral Nervous System Neoplasms / secondary. Peripheral Nervous System Neoplasms / surgery. Radiotherapy. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808267.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


40. Tiftikcioğlu YO, Karaaslan O, Aksoy HM, Aksoy B, Koçer U: Basal cell carcinoma in Turkey. J Dermatol; 2006 Feb;33(2):91-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in Turkey.
  • Basal cell carcinoma (BCC) is the most common form of cancer in Caucasians.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Mohs Surgery / methods. Neoplasm Staging. Prognosis. Prospective Studies. Sex Distribution. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556274.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Bukhari IA, Khalid AJ: Vulvar basal cell carcinoma misdiagnosed for 4 years. Saudi Med J; 2006 Jan;27(1):93-4
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vulvar basal cell carcinoma misdiagnosed for 4 years.
  • Vulvar basal cell carcinoma is a rare cutaneous neoplasm occurring mainly in white postmenopausal females.
  • Here, we report a 59-year-old white female who had vulvar basal cell carcinoma misdiagnosed for 4 years.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Diagnostic Errors. Vulvar Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432603.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


42. Farhadi M, Kamrava SK, Behzadi AH, Rafiezadeh P, Asghari A, Rezvan F, Maleki S: The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma. J Drugs Dermatol; 2010 Feb;9(2):122-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma.
  • OBJECTIVES: A number of investigations have already been carried out to assess the effect of photodynamic therapy (PDT) on primary basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) lesions, but lack of investigations on recurrent lesions or lesions with treatment failure, prompted the authors to carry out this study.
  • The final result of complete response rate in three years of follow up, demonstrated that 16 (64%) patients out of 25 were disease-free from recurrent BCC and SCC (Table 1).
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy


43. Bechert CJ, Stern JB: Basal cell carcinoma with perineural invasion: reexcision perineural invasion? J Cutan Pathol; 2010 Mar;37(3):376-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with perineural invasion: reexcision perineural invasion?
  • BACKGROUND: Perineural invasion (PI) in basal cell and squamous cell carcinomas, especially of the head and neck, has been reported to indicate an increased morbidity.
  • Reexcision perineural invasion (RPI), a benign mimic of tumoral perineural invasion, may present a difficult histologic differential diagnosis.
  • METHODS: We surveyed the medical literature for PI occurring in basal cell carcinomas to investigate the degree to which the reported cases occurred in reexcision specimens vs. primary biopsy specimens.
  • RESULTS: We found large retrospective studies of 14,120 basal cell carcinomas evaluated for PI in which 310 cases of PI were identified (2.2%), and 20 sporadic case reports of basal cell carcinomas with PI.
  • Of 310 cases of basal cell carcinoma with PI, 196 (63%) were in reexcision specimens.
  • CONCLUSION: The high percentage of PI occurring in reexcision specimens vs. primary excisions may indicate that many of the reported cases of basal cell carcinomas with PI are actually examples of RPI.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness / pathology. Neoplasm Seeding. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):76-7 [20840330.001]
  • [CommentIn] J Cutan Pathol. 2012 Nov;39(11):1047-8 [22830947.001]
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):78-9 [20860728.001]
  • (PMID = 19615028.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


44. Kovarik CL, Stewart D, Barnard JJ: Lethal basal cell carcinoma secondary to cerebral invasion. J Am Acad Dermatol; 2005 Jan;52(1):149-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lethal basal cell carcinoma secondary to cerebral invasion.
  • Intracranial invasion by a basal cell carcinoma on the scalp is extremely rare.
  • We present an autopsy case of a 57-year-old woman who developed a large destructive basal cell carcinoma with extension through the calvarium and compression of the dura.
  • We compare 7 similar cases reported in the literature and review the risks for development of these aggressive fatal basal cell carcinomas on the scalp.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Scalp. Skin Neoplasms / pathology
  • [MeSH-minor] Autopsy. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627099.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


45. Aguayo-Leiva IR, Ríos-Buceta L, Jaén-Olasolo P: [Surgical vs nonsurgical treatment of basal cell carcinoma]. Actas Dermosifiliogr; 2010 Oct;101(8):683-92
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical vs nonsurgical treatment of basal cell carcinoma].
  • [Transliterated title] Tratamiento quirúrgico vs. no quirúrgico en el carcinoma basocelular.
  • Numerous therapeutic options are now available for the treatment of basal cell carcinoma.
  • Such a comparison is difficult, probably because efficacy depends on several factors: those related to the tumor, the patient, the technique, and the dermatologist's experience.
  • Then, based on the evidence reviewed, we attempt to provide an outline of the therapeutic strategies recommended in basal cell carcinoma, and the approach to be used in specific situations.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cryosurgery. Fluorouracil / therapeutic use. Follow-Up Studies. Hedgehog Proteins / antagonists & inhibitors. Humans. Interferons / therapeutic use. Laser Therapy. Mohs Surgery. Neoplasm Recurrence, Local. Photochemotherapy. Phytotherapy. Plant Preparations / therapeutic use. Risk Factors. Semecarpus. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Actas Dermosifiliogr. 2011 Oct;102(8):633-4 [21798484.001]
  • (PMID = 20965011.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / Plant Preparations; 0 / SHH protein, human; 9008-11-1 / Interferons; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Farhi D, Dupin N, Palangié A, Carlotti A, Avril MF: Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg; 2007 Oct;33(10):1207-14
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases.
  • BACKGROUND: Reported rates of incomplete excision of basal cell carcinoma (BCC) range from 4% to 16.6%.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local / surgery. Outcome Assessment (Health Care). Skin Neoplasms / surgery. Surgical Procedures, Operative / standards

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903153.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


47. Urosevic M, Kempf W, Zagrodnik B, Panizzon R, Burg G, Dummer R: HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy. Clin Exp Dermatol; 2005 Jul;30(4):422-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy.
  • Basal cell carcinoma (BCC) of the skin represents the most common malignancy in the fair-skinned population worldwide.
  • Interestingly, tumor infiltrating mononuclear cells (TIMC) expressed the HLA-G molecule in BCCs that showed no recurrence.
  • After comparing primary BCCs and BCCs relapsed after radiotherapy, we observed decreased HLA-G expression on tumor cells and the loss of HLA-G expression on TIMC in relapsed BCCs.
  • After radiotherapy, immunobiology of BCC may change resulting in the down-regulation of HLA-G expression on tumor and on tumor-infiltrating cells.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. HLA Antigens / metabolism. Histocompatibility Antigens Class I / metabolism. Neoplasm Recurrence, Local / immunology. Skin Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953086.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


48. Betti R, Facchetti M, Menni S, Crosti C: Basal cell carcinoma of the sole. J Dermatol; 2005 Jun;32(6):450-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the sole.
  • Histologic examination revealed a basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Foot. Neoplasm Invasiveness / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Foot Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043918.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


49. Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS: Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg; 2008 Dec;34(12):1642-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.
  • BACKGROUND: Perineural invasion (PNI) by cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) is an infrequent but not rare complication of traditionally low-morbidity skin cancers that can lead to catastrophic sequelae; 2.5% to 14% of CSCC and approximately 3% of BCC exhibit PNI.
  • MATERIALS AND METHODS: Cases of PNI treated with MMS and radiotherapy were reviewed for recurrence, disease-free follow-up, and adverse events.
  • [MeSH-major] Bell Palsy / etiology. Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / therapy. Skin Neoplasms / complications. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Mohs Surgery. Neoplasm Invasiveness. Peripheral Nerves

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bell's Palsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018830.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Walter A, Barysch MJ, Behnke S, Dziunycz P, Schmid B, Ritter E, Gnjatic S, Kristiansen G, Moch H, Knuth A, Dummer R, van den Broek M: Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res; 2010 Jul 15;16(14):3562-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas.
  • PURPOSE: Nonmelanoma skin cancer is the most common cancer and comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • IgG responses to 36 tumor antigens were measured by Western blotting and ELISA.
  • MHC-I expression and CD8(+) T-cell infiltration were analyzed by immunohistochemistry in BCC and SCC of immunocompetent and immunosuppressed patients and in imiquimod-treated BCC patients.
  • This fits with the increased incidence of SCC in immunosuppressed individuals and may explain the relatively low prevalence of CT-antigen expression in SCC as a result of CD8(+) T-cell-driven immunoediting.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Carcinoma, Basal Cell / immunology. Carcinoma, Squamous Cell / immunology. Histocompatibility Antigens Class I / biosynthesis. Monitoring, Immunologic. Skin Neoplasms / immunology
  • [MeSH-minor] Blotting, Western. CD8-Positive T-Lymphocytes / immunology. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20519358.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


51. Pilloni L, Bianco P, Manieli C, Senes G, Coni P, Atzori L, Aste N, Faa G: Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas. Eur J Histochem; 2009 Apr-Jun;53(2):113-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas.
  • Basal cell carcinoma (BCC) is a very common malignant skin tumor that rarely metastatizes, but is often locally aggressive.
  • An immunohistochemical profile, characterized by reactivity of tumor cells for p53, Ki67 and alpha-SMA has been associated with a more aggressive behaviour in large BCCs.
  • The aim of this study was to verify if also little (<3 cm) basal cell carcinomas can express immunohistochemical markers typical for an aggressive behaviour.
  • [MeSH-major] Actins / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19683985.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


52. Diluvio L, Campione E, Paternò EJ, Orlandi A, Terrinoni A, Chimenti S: Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face. J Dermatolog Treat; 2009;20(2):124-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face.
  • Imiquimod is a 240.3-Da synthetic imidazoquinolinamine (C14H16N4), developed in 1983 and approved in 1997 by the US Food and Drug Administration for the topical treatment of external genital and perianal warts and, more recently, also for actinic keratosis and superficial basal cell carcinomas.
  • We report five cases of patients affected by basal cell carcinomas localized in seborrhoeic areas of the face, successfully treated with topical imiquimod and characterized by the occurrence of eruptive epidermoid cysts at the end-point of therapy.
  • The dermatoscopic evaluation disclosed the presence in all lesions of a common feature characterized by a hyperkeratotic yellow-withish area, resembling 'popcorn', excluding dermoscopic basal cell carcinoma features.
  • As reported in the literature and as observed in our clinical experience, the occurrence of epidermoid cysts, after the topical treatment of basal cell carcinomas with imiquimod, may represent a local immune reaction that is drug-related and is a typical remission pattern in particular anatomical areas.
  • [MeSH-major] Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Administration, Cutaneous. Aged. Antineoplastic Agents / therapeutic use. Biopsy, Needle. Dermoscopy / methods. Dose-Response Relationship, Drug. Drug Administration Schedule. Face. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Sampling Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991155.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


53. Uzquiano MC, Prieto VG, Nash JW, Ivan DS, Gong Y, Lazar AJ, Diwan AH: Metastatic basal cell carcinoma exhibits reduced actin expression. Mod Pathol; 2008 May;21(5):540-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma exhibits reduced actin expression.
  • Basal cell carcinoma is the most common malignancy in Caucasian individuals.
  • Metastatic basal cell carcinoma is extremely rare (with a rate estimated as 0.03%).
  • Actin has been detected in aggressive forms of basal cell carcinoma, but their expression in metastatic lesions is not known.
  • We compared the expression of actin and actin-related cytoskeletal proteins in relatively less aggressive basal cell carcinoma (nodular), aggressive basal cell carcinoma (infiltrative/morpheaform), and metastatic basal cell carcinoma.
  • We studied 12 cases of nodular basal cell carcinoma, 10 cases of infiltrative basal cell carcinoma, and 10 cases of metastatic basal cell carcinoma with immunohistochemistry for alpha-smooth muscle actin, calponin, myosin, and E-cadherin.
  • Expression was interpreted as positive when at least 5% of the tumor exhibited at least weak expression.
  • Five of the ten patients with metastatic basal cell carcinoma had an antecedent history of radiotherapy.
  • Actin was present in 3 of 12 (25%) of the nodular, all 10 of the infiltrative, and 3 of 10 of the metastatic basal cell carcinomas (P<0.05 for metastatic vs infiltrative and nodular vs infiltrative).
  • Calponin was present in 50% of the nodular, 60% of the infiltrative, and 30% of the metastatic basal cell carcinomas (not statistically significant).
  • E-cadherin was present in 75% of the nodular, 70% of the infiltrative, and all of the metastatic basal cell carcinomas (P<0.05 for metastatic vs nodular).
  • [MeSH-major] Actins / biosynthesis. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223552.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Cadherins; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / calponin; EC 3.6.4.1 / Myosins
  •  go-up   go-down


54. Taboada A, Prieto A, Couto I, Brea B, González E: [Invasive basal cell carcinoma of the scalp. A clinical case]. Neurocirugia (Astur); 2010 Oct;21(5):396-400
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Invasive basal cell carcinoma of the scalp. A clinical case].
  • [Transliterated title] Carinoma basocelular invasivo de cuero cabelludo. Caso clínico.
  • Basal cell carcinoma is the most frequent skin malignant neoplasm, although it doesn't usually compromise a vital risk.
  • We present a 62 years old female operated several times because multifocal basal cell carcinoma on her scalp.
  • [MeSH-major] Brain Neoplasms. Carcinoma, Basal Cell. Head and Neck Neoplasms. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042691.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


55. Choi CW, Park HS, Kim YK, Lee SH, Cho KH: Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma. J Dermatol; 2008 Aug;35(8):499-502
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma.
  • Trichoepithelioma (TE) is a benign neoplasm of the skin that resembles basal cell carcinoma (BCC) in its clinical and histological features.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Elastic Tissue / pathology. Keratin-15 / analysis. Neoplasms, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Staining and Labeling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18789069.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Keratin-15
  •  go-up   go-down


56. Hamada S, Kersey T, Thaller VT: Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome. Br J Ophthalmol; 2005 Aug;89(8):992-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome.
  • AIM: To analyse the outcome of basal cell carcinoma (BCC) excision in a subregional (non-Mohs) oculoplastic service.
  • Tumour recurrence rate was derived from the 69 patients with a minimum 5 year follow up.
  • Of those reported incompletely excised 53% contained no tumour at re-excision.
  • [MeSH-major] Blepharoplasty / methods. Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1967 Jun;39(6):619-24 [6026420.001]
  • [Cites] N Engl J Med. 1965 Oct 21;273(17):923-4 [5832875.001]
  • [Cites] J Surg Oncol. 1984 Feb;25(2):79-80 [6694405.001]
  • [Cites] J Surg Oncol. 1985 Jan;28(1):72-4 [3968892.001]
  • [Cites] J Am Acad Dermatol. 1986 Feb;14(2 Pt 1):186-96 [3950119.001]
  • [Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]
  • [Cites] Ophthalmic Surg. 1993 Nov;24(11):755-8 [8290215.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]
  • [Cites] Plast Reconstr Surg. 1982 Jan;69(1):110-6 [7053498.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):631-6 [15051193.001]
  • [Cites] AORN J. 2000 Mar;71(3):552-4, 556-8, 560-4; quiz 565-70 [10736640.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Aug;78(4):430-6 [10990046.001]
  • [Cites] Br J Ophthalmol. 2001 Dec;85(12):1450-4 [11734520.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):257-63 [14871219.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):624-30 [15051192.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):926; author reply 926-7 [16782962.001]
  • [CommentIn] Br J Ophthalmol. 2006 May;90(5):660-1 [16622110.001]
  • (PMID = 16024851.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1772767
  •  go-up   go-down


57. Custódio G, Locks LH, Coan MF, Gonçalves CO, Trevisol DJ, Trevisol FS: Epidemiology of basal cell carcinomas in Tubarão, Santa Catarina (SC), Brazil between 1999 and 2008. An Bras Dermatol; 2010 Nov-Dec;85(6):819-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of basal cell carcinomas in Tubarão, Santa Catarina (SC), Brazil between 1999 and 2008.
  • BACKGROUND: Skin cancer is the most frequent type of neoplasm in Brazil.
  • There are no data on the incidence of basal cell carcinoma in the Southern region of Santa Catarina.
  • OBJECTIVE: To establish epidemiological data on basal cell carcinoma in Tubarão, Santa Catarina, between 1999 and 2008.
  • METHODS: A cross-sectional study was conducted in which anatomopathological reports of basal cell carcinoma from the laboratories of Tubarão, Santa Catarina, were analyzed.
  • We considered the following variables: year of diagnosis, age, gender, city of origin, tumor site, histological subtype, lesion diameter, margin involvement, and relapse.
  • RESULTS: Reports of 3,253 subjects most frequently between the ages of 61 and 80 years diagnosed with basal cell carcinoma were obtained.
  • The incidence of basal cell carcinoma was 164.5 cases per 100,000 inhabitants in 1999 and 295.2 per 100,000 in 2008, showing an increase of 80%.
  • There was an association between males and basal cell carcinoma of the torso and ear, and between females and basal cell carcinoma of the nose.
  • Based on multivariate analysis, lesions of 2 cm in diameter were 5.5 times more likely to present margin involvement, and basal cell carcinoma of the face was 1.8 times more likely to occur (p <0.0001).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308305.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


58. Begnami MD, Quezado M, Pinto P, Linehan WM, Merino M: Adenoid cystic/basal cell carcinoma of the prostate: review and update. Arch Pathol Lab Med; 2007 Apr;131(4):637-40
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for cystic basal cell carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate: review and update.
  • Adenoid cystic/basal cell carcinoma of the prostate is a rare tumor with distinctive histopathologic features.
  • There are only a few publications in the literature concerning the diagnosis, treatment, and prognosis of this neoplasm.
  • OBJECTIVE: To review current literature together with the clinical, pathologic, and immunohistochemical features of adenoid cystic/basal cell carcinoma of the prostate and offer a practical approach to the diagnosis--including the differential diagnosis--of this neoplasm in surgical pathologic specimens.
  • DATA SOURCES: Adenoid cystic/basal cell carcinoma of the prostate is composed of infiltrating basaloid cells forming dilated acinar and cribriform spaces with luminal basementlike material.
  • Differentiation of adenoid cystic/basal cell carcinoma from basal cell hyperplasia and cribriform pattern of acinar adenocarcinoma may be difficult.
  • CONCLUSIONS: Various histologic and immunohistochemical features are helpful in recognizing adenoid cystic/basal cell carcinoma of the prostate.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425398.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


59. Khandwala MA, Lalchan SA, Chang BY, Habib M, Chakrabarty A, Cassells-Brown A: Outcome of periocular basal cell carcinoma managed by overnight paraffin section. Orbit; 2005 Dec;24(4):243-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of periocular basal cell carcinoma managed by overnight paraffin section.
  • BACKGROUND: Surgical excision of periocular skin cancer allows for optimum control in terms of tumour recurrence.
  • All patients had surgical excision of the tumour with a 3-mm margin.
  • If tumour was still present, a further 3-mm margin was excised at the appropriate edge(s) before reconstruction took place.
  • RESULTS: This study yielded 93 basal cell carcinomas (BCCs) of which 86 were of primary origin and 7 were recurrent tumours.
  • The tumour characteristics were as follows: 88% nodular BCCs, 82% had a maximum surface measurement less than or equal to 10 mm, 39.8% were inner canthal and 49.5% were localised to the lower lid.
  • In the 30 (35.4%) cases that required further excision based on the initial histological reports, tumour was seen in only four (11.4%) cases.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Paraffin Embedding / methods
  • [MeSH-minor] Aged. Female. Humans. Male. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354633.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


60. Jankovic I, Kovacevic P, Visnjic M, Jankovic D, Binic I, Jankovic A: Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence? An Bras Dermatol; 2010 Nov-Dec;85(6):872-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence?
  • INTRODUCTION: Basal cell carcinoma is the most common tumor of the eyelid.
  • OBJECTIVE: To define the relationship between margin clearance at excision and the recurrence rate of basal cell carcinoma of the eyelid.
  • METHODS: This prospective study was conducted with 111 patients submitted to surgery for basal cell carcinoma of the eyelid between 2001 and 2003 and followed up for a period of five years.
  • The patients were evaluated according to age, tumor site, recurrence rate and margin clearance at excision.
  • RESULTS: No significant association was found between incomplete tumor excision and recurrence except in patients under 56 years of age, female patients and in the case of tumors of the medial canthus.
  • CONCLUSION: A risk of recurrence in incompletely excised basal cell carcinomas of the eyelid was only confirmed in younger patients, females and for tumors of the medial canthus.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Bras Dermatol. 2011 Mar-Apr;86(2):401; author reply 401-3 [21603839.001]
  • (PMID = 21308312.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


61. Scheibe P, Braumann UD, Kuska JP, Löffler M, Simon JC, Paasch U, Wetzig T: Image-processing chain for a three-dimensional reconstruction of basal cell carcinomas. Exp Dermatol; 2010 Jul 1;19(7):689-91
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-processing chain for a three-dimensional reconstruction of basal cell carcinomas.
  • Basal cell carcinoma (BCC) is the most common malignant skin cancer.
  • For fully automatic delineation of the tumor within the tissue, we apply a fuzzy c-means segmentation method.
  • We used a novel multi-grid form of the non-linear registration introduced by Braumann and Kuska in 2005 effectively suppressing registration runs into local minima (possibly caused by diffuse nature of the tumor).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Imaging, Three-Dimensional / methods. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted / methods. Neoplasm Invasiveness / pathology. Software Design

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20545759.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Denmark
  •  go-up   go-down


62. Katase N, Nagatsuka H, Tsujigiwa H, Gunduz M, Tamamura R, Pwint HP, Rivera RS, Nakajima M, Naomoto Y, Nagai N: Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor. J Oral Pathol Med; 2007 Oct;36(9):550-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor.
  • BACKGROUND: Keratocystic odontogenic tumor (KCOT), also known as odontogenic keratocyst, is a benign cystic neoplasm, which may be associated with nevoid basal cell carcinoma syndrome (NBCCS) and if it does, will occur as multiple cystic lesions.
  • [MeSH-major] Basal Cell Nevus Syndrome / enzymology. Glucuronidase / biosynthesis. Odontogenic Cysts / enzymology. Odontogenic Tumors / enzymology
  • [MeSH-minor] Dentigerous Cyst / enzymology. Gene Expression Regulation, Neoplastic. Heparan Sulfate Proteoglycans / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850439.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Heparan Sulfate Proteoglycans; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


63. Kuzmanov A, Hayrabedyan S, Karaivanov M, Todorova K: Basal cell subpopulation as putative human prostate carcinoma stem cells. Folia Histochem Cytobiol; 2007;45(2):75-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell subpopulation as putative human prostate carcinoma stem cells.
  • The present study examines the expression of p63, glutathione S-transferase-pi (GSTP1) and alpha-methylacyl-CoAracemase (AMACR) in serial slices in proliferative inflammatory atrophy (PIA) in order to implicate that some of the basal cells are probably the putative human prostate carcinoma stem cells (PHPCSC).
  • Quantitative immunohistochemistry analysis (QIHC) of the studied antigen expression levels revealed that there are two populations of p63 basal cells.
  • Type I basal cells had high AMACR, low GSTP1 and p63 expression.
  • Type II basal cells had low AMACR, high GSTP1 and p63 expression.
  • Therefore, we propose that the putative human prostate carcinoma stem cells probably reside within the population of type I basal cells.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597019.001).
  • [ISSN] 0239-8508
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


64. Dabbs DJ, Chivukula M, Carter G, Bhargava R: Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol; 2006 Nov;19(11):1506-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
  • The basal phenotype of breast carcinoma was demonstrated from a study of gene expression profiles, which demonstrated five carcinoma phenotypes with differing immunohistologic profiles and outcomes.
  • The basal phenotype, so-named because of an immunohistologic profile that is similar to myoepithelial cells of the breast, has poor outcomes.
  • While the invasive basal phenotype has been described, there is a paucity of literature regarding the existence or recognition of a precursor lesion.
  • The DCIS types were solid, flat or micropapillary, high nuclear grade, with comedonecrosis and invariably associated with intense lymphoid inflammatory cell infiltration.
  • A DCIS component of solid, flat or micropapillary type exists in the basal phenotype of breast carcinoma, and it demonstrates the same immunophenotype as the invasive carcinoma, typically positive for CK5/6, CK14, CK17, vimentin and EGFR, but negative for ER/PR and HER-2/neu.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Carcinoma, Intraductal, Noninfiltrating / chemistry. Immunohistochemistry
  • [MeSH-minor] Actins / analysis. Adult. DNA-Binding Proteins / analysis. Female. Humans. Keratin-14 / analysis. Keratin-17 / analysis. Keratin-5 / analysis. Keratin-6 / analysis. Necrosis. Neoplasm Invasiveness. Phenotype. Proto-Oncogene Proteins c-kit / analysis. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Trans-Activators / analysis. Transcription Factors. Tumor Suppressor Proteins / analysis. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16941011.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / KRT14 protein, human; 0 / KRT5 protein, human; 0 / Keratin-14; 0 / Keratin-5; 0 / Keratin-6; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


65. Motomura H, Taniguchi T, Harada T, Muraoka M, Ishii M: Aggressive basal cell carcinoma in the nasal region. J Dermatol; 2005 Jun;32(6):424-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive basal cell carcinoma in the nasal region.
  • It is extremely rare for basal cell carcinoma (BCC) to metastasize, so it is often only simply excised.
  • Nasal BCC should be closely examinated, it requires a careful treatment strategy similar to that for other malignant skin tumors.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Neoplasm Invasiveness / pathology. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Mohs Surgery / methods. Neoplasm Staging. Nose. Reconstructive Surgical Procedures. Surgical Flaps. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043913.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


66. Figueroa A, Correnti M, Avila M, Andea A, DeVilliers P, Rivera H: Keratocystic odontogenic tumor associated with nevoid basal cell carcinoma syndrome: similar behavior to sporadic type? Otolaryngol Head Neck Surg; 2010 Feb;142(2):179-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratocystic odontogenic tumor associated with nevoid basal cell carcinoma syndrome: similar behavior to sporadic type?
  • OBJECTIVE: The objective of this study was to analyze the expression of proliferative markers and p53 in keratocystic odontogenic tumor (KCOT) sporadic type and KCOT associated with nevoid basal cell carcinoma syndrome (NBCCS).
  • Immunohistochemical analysis for p53, proliferating cell nuclear antigen (PCNA), and Ki-67 was performed in all 19 cases.
  • [MeSH-major] Basal Cell Nevus Syndrome / metabolism. Basal Cell Nevus Syndrome / pathology. Biomarkers, Tumor / analysis. Odontogenic Cysts / metabolism. Odontogenic Cysts / pathology
  • [MeSH-minor] Cross-Sectional Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20115971.001).
  • [ISSN] 1097-6817
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


67. Shah SM, Konnikov N, Duncan LM, Tannous ZS: The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers Surg Med; 2009 Aug;41(6):417-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas.
  • BACKGROUND AND OBJECTIVE: Basal cell carcinomas (BCCs) have supporting vasculature that could serve as a target for 595 nm pulsed dye laser (PDL).
  • The tumor and 4 mm of peripheral skin were treated using a set of previously optimized laser parameters: one pass, 15 J/cm2 energy, 3 ms pulse length, no cooling, and 7 mm spot size with 10% overlap.
  • The treated area was excised and evaluated histologically for residual tumor.
  • Mean clinical tumor diameter of the complete responders was 1.1 cm (n = 13) versus 2.2 cm (n = 7) for incomplete responders (P-value = 0.005).
  • Tumor histologic types among the complete responders included superficial, nodular, micronodular, and keratinizing.
  • Incompletely responding BCCs showed a significant reduction in tumor burden after PDL treatment, with residual histologic tumor burden ranging from <1% to 29% of the original clinical tumor diameter, compared to 13-68% residual tumor burden for the corresponding controls (P-value = 0.05).
  • CONCLUSIONS: PDL is an effective means of reducing tumor burden in patients with large BCCs and may be an alternative therapy in BCCs <1.5 cm in diameter.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / radiotherapy. Lasers, Dye / therapeutic use. Low-Level Light Therapy. Skin Neoplasms / pathology. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Cohort Studies. Humans. Male. Neoadjuvant Therapy. Neoplasm, Residual. Treatment Outcome. Tumor Burden


68. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • The HER-2/neu (c-erbB-2) gene has been reportedly overexpressed in adenoid cystic carcinomas in other organs, but its status in prostatic ACBCC was uncertain.
  • Benign acini expressed HER-2/neu only in the basal layer.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Gene Expression. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics


69. Kikkawa Y, Sudo R, Kon J, Mizuguchi T, Nomizu M, Hirata K, Mitaka T: Laminin alpha 5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule. Exp Cell Res; 2008 Aug 15;314(14):2579-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laminin alpha 5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule.
  • Laminins are a diverse group of alpha/beta/gamma heterotrimers formed from five alpha, three beta and three gamma chains; they are major components of all basal laminae (BLs).
  • On the other hand, laminin alpha 5 deposition was observed throughout all HCCs tested, regardless of tumor grade.
  • In well-differentiated HCCs, it localized along the trabecules of the tumor.
  • In poorly-differentiated HCCs, it was present in surrounding tumor nodules.
  • In HCC cell lines, laminin alpha 5 heterotrimerized with beta and gamma chains and was secreted into the culture media.
  • In this regard, alpha 3 beta 1/alpha 6 beta 1 integrins and Lutheran/basal cell adhesion molecule (Lu/B-CAM) were expressed in HCC cells.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Cell Adhesion Molecules / metabolism. Integrins / metabolism. Laminin / metabolism. Liver Neoplasms / pathology. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Cell Adhesion. Female. Humans. Immunohistochemistry. Integrin alpha6beta4 / metabolism. Liver / metabolism. Lutheran Blood-Group System. Male. Middle Aged. Protein Transport. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635166.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAM protein, human; 0 / Cell Adhesion Molecules; 0 / Integrin alpha6beta4; 0 / Integrins; 0 / Laminin; 0 / Lutheran Blood-Group System; 0 / Neoplasm Proteins; 0 / laminin alpha5
  •  go-up   go-down


70. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res; 2006 Mar 1;12(5):1533-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
  • PURPOSE: Basal-like phenotype tumors are frequently found among BRCA1 germ-line mutated breast carcinomas.
  • The aim of this study was to determine whether basal-like phenotype and fascin were related in both sporadic and familial tumors and with prognosis in node-negative sporadic breast cancers.
  • Tumors that were estrogen receptor/HER2 negative and cytokeratin 5/6 and/or epidermal growth factor receptor positive were considered to have a basal-like phenotype.
  • RESULTS: A basal-like phenotype was found in 11.9% of sporadic cancers.
  • Among patients not receiving adjuvant chemotherapy, a basal-like phenotype was associated with poor prognosis (P = 0.001, log-rank test) whereas no such association was found in patients receiving it.
  • Tumors with a basal-like phenotype showed local recurrence (17.4%) or visceral metastasis (13%) but not bone metastasis (P = 0.001).
  • Fascin expression was observed in 25.1% of sporadic invasive breast carcinomas and was associated with the basal-like phenotype, but not with prognosis or recurrence pattern.
  • CONCLUSIONS: Basal-like tumors had a tendency towards visceral metastasis and their prognosis was dependent on the use of postoperative chemotherapy.
  • Although fascin expression was associated with the basal-like phenotype, it was not associated with their metastatic behavior.
  • [MeSH-major] Breast Neoplasms / metabolism. Carrier Proteins / metabolism. Lymph Nodes / metabolism. Microfilament Proteins / metabolism. Neoplasms, Basal Cell / metabolism
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Aged, 80 and over. BRCA1 Protein / metabolism. BRCA2 Protein / metabolism. Female. Humans. Keratin-5. Keratin-6. Keratins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Phenotype. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533778.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / BRCA1 Protein; 0 / BRCA2 Protein; 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Microfilament Proteins; 0 / Receptors, Estrogen; 146808-54-0 / fascin; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


71. Ericson MB, Uhre J, Strandeberg C, Stenquist B, Larkö O, Wennberg AM, Rosén A: Bispectral fluorescence imaging combined with texture analysis and linear discrimination for correlation with histopathologic extent of basal cell carcinoma. J Biomed Opt; 2005 May-Jun;10(3):034009
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bispectral fluorescence imaging combined with texture analysis and linear discrimination for correlation with histopathologic extent of basal cell carcinoma.
  • Fluorescence imaging has been shown to be a potential complement to visual inspection for demarcation of basal cell carcinoma (BCC), which is the most common type of skin cancer.
  • In this work, we have tried to further improve the ability of this technique to discriminate between areas of tumor and normal skin by implementing texture analysis and Fisher linear discrimination (FLD) on bispectral fluorescence data of BCCs located on the face.
  • [MeSH-major] Algorithms. Artificial Intelligence. Carcinoma, Basal Cell / pathology. Image Interpretation, Computer-Assisted / methods. Microscopy, Fluorescence / methods. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Computer Simulation. Data Interpretation, Statistical. Discriminant Analysis. Female. Humans. Linear Models. Male. Middle Aged. Models, Biological. Neoplasm Invasiveness. Neoplasm Staging / methods. Reproducibility of Results. Sensitivity and Specificity. Severity of Illness Index. Spectrometry, Fluorescence / methods. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Society of Photo-Optical Instrumentation Engineers.
  • (PMID = 16229653.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Lovatt TJ, Lear JT, Bastrilles J, Wong C, Griffiths CE, Samarasinghe V, Roebuck J, Ramachandran S, Smith AG, Jones PW, Fryer AA, Strange RC: Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. J Am Acad Dermatol; 2005 Mar;52(3 Pt 1):468-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors.
  • BACKGROUND: Patients with basal cell carcinoma (BCC) frequently develop further tumors during follow-up.
  • OBJECTIVE: We sought to elucidate the relative effects of pattern of ultraviolet radiation exposure, and site and histologic type of the first tumor, on the rate of increase in BCC numbers.
  • METHODS: We used negative binomial regression analysis to study the association of selected variables on the rate of increase in BCC numbers in 266 Caucasian patients who first presented with a tumor on the head/neck or trunk with nodular or superficial histology.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761425.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Østergaard J, Boberg-Ans J, Prause JU, Heegaard S: Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):615-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva.
  • BACKGROUND: To report the clinical and histopathological characteristics of a patient with a primary basal cell carcinoma (BCC) of the caruncle with seeding of the tumour to the conjunctiva.
  • Clinical examination revealed a pale lobulated tumour without skin involvement.
  • The tumour was excised.
  • Three years later a small polypoid tumour developed in the inferior fornix of the same eye.
  • Microscopically, both neoplasms were composed of infiltrative islands of basaloid tumour cells, scattered mitoses and peripheral palisading consistent with the diagnosis of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Conjunctival Neoplasms / secondary. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surv Ophthalmol. 1993 Sep-Oct;38(2):169-92 [8235999.001]
  • [Cites] Arch Ophthalmol. 1998 Oct;116(10):1373-4 [9790642.001]
  • [Cites] Arch Ophthalmol. 2000 Sep;118(9):1296-8 [10980780.001]
  • [Cites] Br J Ophthalmol. 1973 Nov;57(11):836-7 [4785248.001]
  • [Cites] Am J Ophthalmol. 1982 Nov;94(5):591-3 [7148940.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]
  • [Cites] Cornea. 1987;6(2):78-116 [3301209.001]
  • [Cites] Indian J Ophthalmol. 1975 Oct;23(3):33-4 [1236314.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Oct;78(5):547-52 [11037913.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1585-7 [9400796.001]
  • (PMID = 15614536.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Paavilainen V, Aaltonen M, Tuominen J, Saari KM: Histological characteristics of basal cell carcinoma of the eyelid. Ophthalmic Res; 2007;39(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological characteristics of basal cell carcinoma of the eyelid.
  • PURPOSE: To evaluate the histological subtypes of basal cell carcinoma (BCC) of the eyelid and to determine their effect on the size, depth of invasion and need of retreatment of a nonselected patient material seen in south-western Finland.
  • The size of the tumor and the depth of invasion correlated directly with each other.
  • CONCLUSIONS: The nodular subtype of BCC should be regarded as a potentially invasive and recurrent tumor.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164577.001).
  • [ISSN] 0030-3747
  • [Journal-full-title] Ophthalmic research
  • [ISO-abbreviation] Ophthalmic Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


75. Vogler N, Meyer T, Akimov D, Latka I, Krafft C, Bendsoe N, Svanberg K, Dietzek B, Popp J: Multimodal imaging to study the morphochemistry of basal cell carcinoma. J Biophotonics; 2010 Oct;3(10-11):728-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal imaging to study the morphochemistry of basal cell carcinoma.
  • Basal cell carcinoma is the most abundant malignant neoplasm in humans, the pathology of which is characterized by an abnormal proliferation of basal cells.
  • Basal cell carcinoma can show a variety of different morphologies, which are based on different cellular biology.
  • Thus, our work aims at establishing an unsupervised tissue classification method based on multimodal imaging and the application of chemometrics to discriminate basal cell carcinoma from non-diseased tissue.
  • A case study applying multimodal imaging to ex-vivo sections of basal cell carcinoma is presented.
  • In doing so, we apply a combination of various linear and non-linear imaging modalities, i.e. fluorescence, Raman and second-harmonic generation microscopy, to study the morphochemistry of basal cell carcinoma.
  • The joint information content obtained by such multimodal approach in studying various aspects of the malignant tissue alterations associated with basal cell carcinoma is discussed.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Molecular Imaging / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20648521.001).
  • [ISSN] 1864-0648
  • [Journal-full-title] Journal of biophotonics
  • [ISO-abbreviation] J Biophotonics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Muller FM, Dawe RS, Moseley H, Fleming CJ: Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatol Surg; 2009 Sep;35(9):1349-54
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome.
  • BACKGROUND: Mohs micrographic surgery (MMS) is recognized globally as the criterion standard for high-risk basal cell carcinoma (BCC).
  • The main advantage of MMS over conventional surgery is the chance of complete tumor removal, but it is also thought, based on experience, to be tissue sparing.
  • OBJECTIVE: To determine whether MMS leaves smaller surgical defects than standard surgery.
  • In the MMS group, tumors were excised with 2-mm margins and subsequent stages of MMS until the tumor was completely removed.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery / methods. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Single-Blind Method. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500127.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00571363
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N: Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol; 2007 Jan;56(1):91-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.
  • BACKGROUND: The incidence of basal cell carcinoma (BCC) is increasing.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Curettage. Electrocoagulation. Facial Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190625.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Sellheyer K, Krahl D: Basal cell (trichoblastic) carcinoma common expression pattern for epithelial cell adhesion molecule links basal cell carcinoma to early follicular embryogenesis, secondary hair germ, and outer root sheath of the vellus hair follicle: A clue to the adnexal nature of basal cell carcinoma? J Am Acad Dermatol; 2008 Jan;58(1):158-67
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell (trichoblastic) carcinoma common expression pattern for epithelial cell adhesion molecule links basal cell carcinoma to early follicular embryogenesis, secondary hair germ, and outer root sheath of the vellus hair follicle: A clue to the adnexal nature of basal cell carcinoma?
  • BACKGROUND: Basal cell carcinoma (BCC) is still viewed by many dermatologists as a tumor of the interfollicular epidermis, although references were made early in the dermatopathologic literature to the resemblance of BCC to the hair follicle.
  • OBJECTIVE: Our aim was to characterize the common expression pattern for the epithelial cell adhesion molecule (Ep-CAM) in BCCs, various stages of follicular embryogenesis, and adult hair follicles and, thereby, in analogy point to the similarity between BCC and the hair follicle.
  • CONCLUSION: BCC expresses the cell-cell adhesion molecule Ep-CAM similar to the embryonic hair germ, the secondary hair germ of the terminal hair follicle, and the outer root sheath of the vellus hair follicle.
  • We suggest that this may be a clue to the adnexal nature of BCC and propose that BCC is the most primitive follicular tumor.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Carcinoma, Basal Cell / metabolism. Cell Adhesion Molecules / metabolism. Hair Follicle / embryology. Hair Follicle / metabolism. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158927.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / tumor-associated antigen GA733
  •  go-up   go-down


79. Pérez de la Fuente T, González González I: Recurrent basal cell carcinoma of the lower limb with tibial invasion. J Cutan Med Surg; 2006 Jan-Feb;10(1):36-40
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basal cell carcinoma of the lower limb with tibial invasion.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common skin malignancy and is most prevalent on the head and neck region, although BCC can occur in other sites, including the lower limbs.
  • [MeSH-major] Bone Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Tibia
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Imaging, Three-Dimensional. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241571.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Da Silva L, Clarke C, Lakhani SR: Demystifying basal-like breast carcinomas. J Clin Pathol; 2007 Dec;60(12):1328-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demystifying basal-like breast carcinomas.
  • "Basal" breast cancers are dominating the breast research literature at present and pathologists are under increasing pressure to evaluate for such a phenotype by their surgical and oncological colleagues.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasms, Basal Cell / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Breast / pathology. Female. Humans. Middle Aged. Neoplasm Proteins / metabolism. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45 [9701363.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):119-29 [9737789.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1433-6 [10197608.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] J Natl Cancer Inst. 1963 Feb;30:269-87 [13999855.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):422-7 [11487275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] J Pathol. 2002 Jan;196(1):32-6 [11748639.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2310-8 [11981002.001]
  • [Cites] Endocr Relat Cancer. 2002 Sep;9(3):183-95 [12237246.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):1-8 [12610349.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):307-19 [16424897.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1028-35 [16280056.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] Breast Cancer Res. 2005;7(4):143-8 [15987465.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] J Pathol. 2005 Nov;207(3):260-8 [16167361.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Histopathology. 2006 Jul;49(1):10-21 [16842242.001]
  • [Cites] Histopathology. 2006 Jul;49(1):22-34 [16842243.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91 [16857790.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:139-48 [16869747.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]
  • [Cites] J Pathol. 2006 Aug;209(4):445-53 [16739104.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):1033-40 [16897746.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5846-53 [16998499.001]
  • [Cites] Am J Surg Pathol. 2006 Nov;30(11):1357-66 [17063074.001]
  • [Cites] Stem Cell Rev. 2005;1(3):207-13 [17142857.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R61 [17069663.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):488-97 [17255270.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):417-26 [17325484.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):235-44 [17329194.001]
  • [Cites] Virchows Arch. 2007 Jan;450(1):73-80 [17123107.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R4 [17217540.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R16 [17263897.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1134-9 [10534158.001]
  • [Cites] J Pathol. 1999 Dec;189(4):521-6 [10629552.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):197-202 [10680887.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1206-10 [10728676.001]
  • [Cites] Histopathology. 2000 Aug;37(2):175-81 [10931242.001]
  • [Cites] Mod Pathol. 2006 May;19(5):617-21 [16528377.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] J Clin Pathol. 2006 Jul;59(7):729-35 [16556664.001]
  • [Cites] BMC Genomics. 2006;7:127 [16729877.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 [14519755.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:59-72 [14521516.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1422-8 [15054466.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Am J Pathol. 1966 Aug;49(2):301-7 [4287836.001]
  • [Cites] Am J Pathol. 1967 Feb;50(2):335-60 [6016510.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • [Cites] Cancer. 1977 Oct;40(4):1365-85 [907958.001]
  • [Cites] Cancer Res. 1982 Nov;42(11):4763-70 [6290045.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Differentiation. 1983;23(3):256-69 [6189757.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Nov;82(21):7409-13 [2414776.001]
  • [Cites] J Histochem Cytochem. 1986 Jul;34(7):869-81 [2423579.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;51(3):265-75 [2874659.001]
  • [Cites] Breast Cancer Res Treat. 1987 Oct;10(1):11-20 [2446682.001]
  • [Cites] Am J Pathol. 1989 Mar;134(3):571-9 [2466404.001]
  • [Cites] Am J Pathol. 1991 Mar;138(3):751-63 [1705754.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):591-5 [2021545.001]
  • [Cites] J Pathol. 1996 Aug;179(4):386-91 [8869285.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1588-92 [9563465.001]
  • (PMID = 17496191.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 73
  • [Other-IDs] NLM/ PMC2095578
  •  go-up   go-down


81. Lamon T, Gerard S, Meyer N, Losfeld B, Abellan van Kan G, Balardy L, Vellas B: Exceptional bone metastasis of basal cell carcinoma in Gorlin-Goltz syndrome. Dermatology; 2010;220(1):57-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exceptional bone metastasis of basal cell carcinoma in Gorlin-Goltz syndrome.
  • BACKGROUND: Basal cell carcinoma (BCC), the most prevalent form of cancer worldwide, is a malignant skin neoplasm.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / secondary. Focal Dermal Hypoplasia / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] European Continental Ancestry Group. Humans. Male. Middle Aged. Neoplasm Metastasis. Pain / etiology. Receptors, Cell Surface / genetics

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996568.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


82. Tiftikcioğlu YO, Karaaslan O, Aksoy HM, Aksoy B, Koçer U: Basal cell carcinoma in Turkey. J Dermatol; 2005 Dec;32(12):946-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in Turkey.
  • Basal cell carcinoma (BCC) is the most common form of cancer in Caucasians.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / diagnosis. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Risk Assessment. Sex Distribution. Survival Rate. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471455.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Hassanein AM, Proper SA, Depcik-Smith ND, Flowers FP: Peritumoral fibrosis in basal cell and squamous cell carcinoma mimicking perineural invasion: potential pitfall in Mohs micrographic surgery. Dermatol Surg; 2005 Sep;31(9 Pt 1):1101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral fibrosis in basal cell and squamous cell carcinoma mimicking perineural invasion: potential pitfall in Mohs micrographic surgery.
  • BACKGROUND: Perineural invasion (PI) in cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) is linked to an aggressive course.
  • OBJECTIVE: To describe the morphologic changes associated with PF and to determine the incidence of PF and PI in Mohs frozen sections of BCC and SCC.
  • The latter was defined as the presence of concentric layers of fibrous tissue that either surround and/or were surrounded by tumor formations mimicking perineural or intraneural invasion.
  • It shows concentric layers of fibrous tissue surrounding and/or surrounded by tumor formations and resembles carcinomatous perineural and/or intraneural invasion.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Fibrosis / pathology. Humans. Mohs Surgery. Neoplasm Invasiveness


84. Farah-Klibi F, Ferchiou M, Kourda J, El Amine O, Ferjaoui M, Ben Jilani S, Zermani R: [Parotid basal cell adenoma of membranous type]. Tunis Med; 2009 Feb;87(2):149-51
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parotid basal cell adenoma of membranous type].
  • [Transliterated title] Adenome a cellules basales de type membraneux de la parotide.
  • INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.
  • AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.
  • So the diagnosis of metastatic malignant salivary gland tumor was suspected.
  • Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.
  • CONCLUSION: The BCA is a benign tumor located generally in the parotid gland.
  • When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis. Sarcoidosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522450.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


85. Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR, Thomas GJ: alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res; 2008 May 1;68(9):3295-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation.
  • Basal cell carcinoma (BCC) is the most prevalent cancer in the Western world and its incidence is increasing.
  • These cells expressed alpha v beta 6 and were invasive, although inhibition of alpha v beta 6 had no direct effect on cell invasion.
  • Paracrine secretion of hepatocyte growth factor/scatter factor by these myofibroblasts promoted c-Met-dependent tumor invasion in both Transwell and three-dimensional organotypic assays.
  • [MeSH-major] Antigens, Neoplasm / physiology. Carcinoma, Basal Cell / pathology. Integrins / physiology. Skin Neoplasms / pathology. Stromal Cells / pathology
  • [MeSH-minor] Animals. Antibodies / pharmacology. Cell Movement / genetics. Cells, Cultured. Hepatocyte Growth Factor / metabolism. Humans. Keratinocytes / metabolism. Kruppel-Like Transcription Factors / genetics. Kruppel-Like Transcription Factors / metabolism. Mink. Neoplasm Invasiveness. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Proto-Oncogene Proteins c-met / metabolism. RNA, Small Interfering / pharmacology. Transcription Factors / genetics. Transcription Factors / metabolism. Transforming Growth Factor beta1 / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451156.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / Integrins; 0 / Kruppel-Like Transcription Factors; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / integrin alphavbeta6; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


86. Karve SJ, Feldman SR, Yentzer BA, Pearce DJ, Balkrishnan R: Imiquimod: a review of basal cell carcinoma treatments. J Drugs Dermatol; 2008 Nov;7(11):1044-51
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod: a review of basal cell carcinoma treatments.
  • Basal cell carcinoma (BCC) is regarded as the most prevalent malignant skin tumor in whites.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Neoplasms, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Humans. Mohs Surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Quality of Life

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110735.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 50
  •  go-up   go-down


87. Jakobiec FA, Zakka FR, Hatton MP: Eyelid basal cell carcinoma developing in an epidermoid cyst: a previously unreported event. Ophthal Plast Reconstr Surg; 2010 Nov-Dec;26(6):491-4
MedlinePlus Health Information. consumer health - Eyelid Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid basal cell carcinoma developing in an epidermoid cyst: a previously unreported event.
  • Local excision led to the microscopic discovery of 2 epidermoid cysts, one of which harbored a basal cell carcinoma arising from its orthokeratinizing squamous cell lining.
  • BER-EP4-positive immunostaining confirmed the basal cell nature of the neoplasm.
  • This is the first example in the eyelid of an epidermoid cyst displaying malignant transformation.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Cell Transformation, Neoplastic / pathology. Epidermal Cyst / pathology. Eyelid Diseases / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Visual Acuity

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736874.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / human epithelial antigen-125
  •  go-up   go-down


88. Archontaki M, Stavrianos SD, Korkolis DP, Arnogiannaki N, Vassiliadis V, Liapakis IE, Christ H, Rapidis AD, Kokkalis G: Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature. Anticancer Res; 2009 Jul;29(7):2655-63
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature.
  • BACKGROUND: Giant basal cell carcinoma (GBCC) is an aggressive malignant neoplasm.
  • Because of the rarity of the tumor and its recognized high risk of recurrence, there are no guidelines for its treatment.
  • A clinical database was established in order to define the behavior of this tumor, prognostic factors and optimal treatment.
  • It develops as long-standing dermal tumor with mean disease duration of 14.5 years and is most commonly located on the back, followed by the face and upper extremity.
  • Wide local excision of the tumor with or without postoperative radiochemotherapy represents the optimal treatment.
  • CONCLUSION: Optimal management of GBCC consists of wide local excision with histologically confirmed tumor-free margins, frequently followed by adjuvant therapy.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596942.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 54
  •  go-up   go-down


89. Griffiths RW, Suvarna SK, Stone J: Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg; 2005 Sep;58(6):795-805
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do basal cell carcinomas recur after complete conventional surgical excision?
  • For 1378 patients treated in the 11 years 1988-1998 by conventional excision of 1635 basal cell carcinomas, 1516 first index lesions were histologically completely excised.
  • All incompletely excised lesions whether or not re-excised were excluded.
  • The median interval to recurrence was 41 months (4 months-8 years 10 months), with median lateral clearance margin around the primary tumour of 2 mm (0.3-6.8 mm).
  • The median lateral clearance margin around the primary tumour was 4.1 mm (0.8-5.8 mm).
  • Two thirds of possible and probable recurrences occurred in the temple and forehead, although these sites represented only 22% of all lesions, which may rather suggest new lesions in an area of field change as opposed to residual disease.
  • These figures indicate there is a low order of probability for the incidence of recurrent basal cell carcinoma during minimum 5 years follow period after conventional surgical excision and conventional histological assessment of tumour resection margins.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2007;60(4):451-3 [17349608.001]
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2006;59(11):1247 [17046636.001]
  • (PMID = 16086990.001).
  • [ISSN] 0007-1226
  • [Journal-full-title] British journal of plastic surgery
  • [ISO-abbreviation] Br J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Handa Y, Kato Y, Ishikawa H, Tomita Y: Giant superficial basal cell carcinoma of the scrotum. Eur J Dermatol; 2005 May-Jun;15(3):186-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant superficial basal cell carcinoma of the scrotum.
  • The majority of basal cell carcinomas (BCCs) occur on sun-exposed areas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Scrotum. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Japan. Male. Neoplasm Staging. Rare Diseases. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908305.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Thomas PB, Liu YH, Zhuang FF, Selvam S, Song SW, Smith RE, Trousdale MD, Yiu SC: Identification of Notch-1 expression in the limbal basal epithelium. Mol Vis; 2007 Mar 01;13:337-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of Notch-1 expression in the limbal basal epithelium.
  • PURPOSE: To determine whether Notch-1, a ligand-activated transmembrane receptor known to maintain cells in an undifferentiated state, primarily progenitor cells in other systems, could be used as a stem cell marker in human limbal epithelium.
  • RESULTS: Notch-1 was found to be expressed in the limbal basal region where stem cells reside.
  • Notch-1 antigenicity was more pronounced in cell clusters, mainly in the palisades of Vogt.
  • Double staining for ABCG2 and Notch-1 showed some ABCG2-positive cells co-expressing Notch-1 in the limbal basal epithelium, indicating that Notch-1-expressing cells might be a unique subpopulation of cells with stem cell properties.
  • CONCLUSIONS: Immunofluorescence data shows that Notch-1 could be a possible marker for the stem cells in the limbal basal epithelium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1989 Aug;3(8):1113-29 [2792756.001]
  • [Cites] Cell. 1989 Apr 21;57(2):201-9 [2702690.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1991 May;32(6):1864-75 [2032808.001]
  • [Cites] Cornea. 1994 Sep;13(5):389-400 [7995060.001]
  • [Cites] Cell. 1995 Jan 13;80(1):83-93 [7813021.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6414-8 [7604005.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):14-21 [7542296.001]
  • [Cites] Mech Dev. 1995 Sep;53(1):73-85 [8555113.001]
  • [Cites] J Hematother. 1996 Jun;5(3):237-45 [8817390.001]
  • [Cites] Cornea. 1996 Nov;15(6):549-56 [8899265.001]
  • [Cites] Development. 1996 Dec;122(12):3765-73 [9012498.001]
  • [Cites] Lancet. 1997 Apr 5;349(9057):990-3 [9100626.001]
  • [Cites] J Cell Sci. 1998 Oct;111 ( Pt 19):2867-75 [9730979.001]
  • [Cites] J Cell Sci. 1998 Nov;111 ( Pt 21):3179-88 [9763512.001]
  • [Cites] Development. 1999 Apr;126(8):1689-702 [10079231.001]
  • [Cites] EMBO J. 1999 Apr 15;18(8):2196-207 [10205173.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Development. 1999 Jun;126(11):2409-18 [10226000.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):314-22 [15665828.001]
  • [Cites] J Cell Sci. 2005 Apr 15;118(Pt 8):1715-24 [15811951.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):964-8 [15959516.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6640-50 [16061644.001]
  • [Cites] Indian J Ophthalmol. 1999 Mar;47(1):3-9 [16130277.001]
  • [Cites] Dev Biol. 2006 Feb 1;290(1):66-80 [16360140.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 16;344(4):1278-83 [16650829.001]
  • [Cites] Stem Cells. 2006 May;24(5):1265-73 [16424398.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8598-607 [16951173.001]
  • [Cites] J Invest Dermatol. 2000 Mar;114(3):413-20 [10692098.001]
  • [Cites] Surv Ophthalmol. 2000 Mar-Apr;44(5):415-25 [10734241.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):86-93 [10891515.001]
  • [Cites] Cornea. 2000 Jul;19(4):421-6 [10928750.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1278-81 [11062542.001]
  • [Cites] J Exp Med. 2000 Nov 6;192(9):1365-72 [11067884.001]
  • [Cites] Dev Biol. 2000 Dec 15;228(2):151-65 [11112321.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] Genes Dev. 2002 Apr 1;16(7):846-58 [11937492.001]
  • [Cites] Annu Rev Neurosci. 2002;25:471-90 [12052917.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):416-21 [12590261.001]
  • [Cites] Semin Cell Dev Biol. 2003 Apr;14(2):143-50 [12651098.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):2972-82 [12843129.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4275-81 [14507871.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):393-8 [14977776.001]
  • [Cites] Stem Cells. 2004;22(3):355-66 [15153612.001]
  • [Cites] Exp Eye Res. 2004 Jul;79(1):41-9 [15183099.001]
  • [Cites] Development. 2004 Oct;131(20):4955-64 [15371309.001]
  • [Cites] Nature. 1971 Feb 19;229(5286):560-1 [4925352.001]
  • [Cites] J Cell Biol. 1986 Jul;103(1):49-62 [2424919.001]
  • [Cites] J Cell Biol. 1991 May;113(3):657-69 [2016340.001]
  • (PMID = 17392684.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY003040; United States / NEI NIH HHS / EY / R03 EY014392; United States / NEI NIH HHS / EY / EY014392; United States / NEI NIH HHS / EY / EY03040
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Antigens, CD29; 0 / Integrin alpha6; 0 / Neoplasm Proteins; 0 / Receptors, Notch
  • [Other-IDs] NLM/ PMC2633467
  •  go-up   go-down


92. Shah SA, Obaidullah, Fahimullah: An assessment of incomplete facial Basal cell carcinoma excision. J Coll Physicians Surg Pak; 2005 Mar;15(3):149-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An assessment of incomplete facial Basal cell carcinoma excision.
  • OBJECTIVE: To determine the rate and cause(s) of incomplete excision of basal cell carcinoma, occurring on face.
  • PATIENTS AND METHODS: Patients with basal cell carcinoma of the face reporting to the OPD were included in the study and were booked for surgery.
  • After excision, all tumors specimens were marked at 12 o'clock and sent to laboratory for histopathology to confirm the diagnosis and to know the completeness/incompleteness of tumor excision.
  • If biopsy reported residual tumor in any of the margins it was noted and projected as percentage for the purpose of our results.
  • RESULTS: Out of 56 patients, 49 (87.5%) had complete excision of tumor.
  • Six (10.7%) had residual tumor while in one (1.7%) patient, biopsy report failed to mention the involvement/clearance of margins.
  • Six patients with residual tumor were given postoperative radiotherapy.
  • All patients were followed for a minimum of 2-1/2 years (critical period for recurrence) with careful watch on those with residual tumor.
  • CONCLUSION: Chances of incomplete tumor excision are more on the mid face region.
  • Patients with residual tumor are more prone to recurrence.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. Developing Countries. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Mohs Surgery / methods. Neoplasm Staging. Pakistan / epidemiology. Prognosis. Retrospective Studies. Risk Assessment. Sex Distribution. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808092.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


93. Naumann IC, Cordes SR: Giant basal cell carcinoma of the forehead with extensive intracranial involvement. Ann Otol Rhinol Laryngol; 2007 Sep;116(9):663-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma of the forehead with extensive intracranial involvement.
  • Basal cell carcinoma (BCC) is the most common malignant skin lesion and is frequently curatively treated with local excision.
  • Despite its fairly benign growth pattern, BCC should never be underestimated, and care should be taken not only in the complete primary excision but also in cancer surveillance.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Forehead. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / methods. Reconstructive Surgical Procedures / methods. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926588.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Fadare O, Tavassoli FA: Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol; 2008 Mar;5(3):149-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathologic aspects of basal-like breast cancers.
  • The molecular subclasses of cohorts classified by the 'intrinsic' gene set include the luminal A and B, erbB-2+, normal-breast-like, and basal-like tumors.
  • Basal-like breast cancers have been reported to be associated with worse overall and disease-free survival compared with the luminal A subtype.
  • In addition, there is an immunohistochemical surrogate for the basal-like profile, which has considerably facilitated their study in non-specialty laboratories.
  • Basal-like breast carcinomas have markedly reduced expression of genes related to estrogen receptors and erbB-2, and express proteins that are characteristic of the normal myoepithelial cell.
  • This Review appraises the current state of knowledge on the clinical and pathologic features of breast cancers classified as 'basal-like' by gene-expression profiling and/or immunohistochemical criteria.
  • Similarly to tumors of luminal epithelial differentiation, carcinomas of the 'basal' type have a spectrum of morphologic and clinical characteristics.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Female. Gene Expression Profiling. Genes, BRCA1. Germ-Line Mutation. Humans. Neoplasm Invasiveness. Neoplasms, Basal Cell / drug therapy. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Phenotype. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212769.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 100
  •  go-up   go-down


95. Unlü RE, Altun S, Ssensöz O: Leishmania scar: a risk factor for the development of basal cell carcinomas. J Craniofac Surg; 2007 May;18(3):708-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leishmania scar: a risk factor for the development of basal cell carcinomas.
  • Basal cell carcinoma is a malignant epithelial neoplasm of skin that usually arises in areas of chronic sun exposure.
  • We present a case of basal cell carcinoma arising on a leishmania scar on the nasal dorsum 30 years after the primary lesion.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Cicatrix / pathology. Leishmaniasis, Cutaneous / pathology. Nose Diseases / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17538345.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Gao LX, Yang GZ, Ding HY, Li L: [Morphological features of basal-like subtype invasive carcinoma of breast]. Zhonghua Bing Li Xue Za Zhi; 2008 Feb;37(2):83-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphological features of basal-like subtype invasive carcinoma of breast].
  • OBJECTIVE: To summarize the morphological features of basal-like subtype of invasive breast carcinoma (BLSIBC), and to look for diagnostic clues for its recognition.
  • Five subtypes were classified according to immunophenotypes: luminal A subtype (ER+/HER2-), luminal B subtype (ER+/ HER2+), normal breast-like subtype (ER/HER2-), HER2-overexpressing subtype and BLSIBC which was identified with at least one kind of basal-like cytokeratins or markers of myoepithelium and ER/HER2.
  • The microscopic features of basal-like subtype were also analyzed.
  • RESULTS: The number of luminal A case was 48 (44.0%), luminal B 15 (13.8%), HER2 over-expressing 15 (13.6%), normal breast-like 10 (9.1%), basal-like subtype 19 (17.4%).
  • Of the 19 basal-like subtype, CK5/6 was expressed in 16 cases, CK8/18 in 17 cases, CK14 in 11 cases, 34betaE12 in 18 cases, p63 in 5 cases, CD10 in 6 cases, and calponin in 1 case.
  • The diameter of the BLSIBC cases was 1.2-7 cm (averagely 3.9 cm) , and in 6 cases, the tumor diameter was >5 cm.
  • Compared to non basal subtype, there were significantly more high grade cases (P <0.01).
  • The morphological features of basal-like subtype were summarized as the followings: pushing margin (13 cases), lymphocytic tissue hyperplasia (18 cases), nest or sheet arrangement (18 cases), nucleus grade 3 and scattered giant or bizarre nuclei (17 cases), syncytial growth (7 cases), and comedo-like necrosis (17 cases).
  • The frequency of these features were significantly more common than non basal subtype (P <0.01).
  • CONCLUSION: The morphologic diagnostic features of BLSIBC are pushing margins, lymphocyte infiltration, comedo-like necrosis, gigantic cell and syncytial growth.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis
  • [MeSH-minor] Female. Genes, erbB-2 / physiology. Humans. Immunohistochemistry. Keratin-5 / analysis. Magnetic Resonance Imaging. Male. Mammography / instrumentation. Mammography / methods. Neoplasm Invasiveness / physiopathology. Prognosis. Receptor, Epidermal Growth Factor / genetics. Receptors, Progesterone / analysis. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681317.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-5; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


97. Goh BK, Ang P, Wu YJ, Goh CL: Characteristics of basal cell carcinoma amongst Asians in Singapore and a comparison between completely and incompletely excised tumors. Int J Dermatol; 2006 May;45(5):561-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of basal cell carcinoma amongst Asians in Singapore and a comparison between completely and incompletely excised tumors.
  • BACKGROUND: Most published series of basal cell carcinomas (BCCs) are based on Caucasian populations.
  • Incompletely excised BCCs were more likely than completely excised lesions to be located on the mid-face and trunk (P = 0.003), but there was no significant correlation with tumor size, tumor duration, or patient age, race, and gender.
  • Conventional surgical excision with margin control achieves a satisfactory tumor clearance rate of 84.9%.
  • Incomplete excision is associated with tumor location on the mid-face and trunk rather than tumor size or duration.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700792.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R: Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study. Int J Dermatol; 2008 Jan;47(1):78-82
Hazardous Substances Data Bank. SOLASODINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study.
  • OBJECTIVE: To assess the safety and efficacy of a 0.005% mixture of solasodine glycosides (Zycure) in the treatment of basal cell carcinoma.
  • MAIN OUTCOME MEASURES: The primary efficacy endpoint was histologically confirmed clearance of the basal cell carcinoma (2-mm punch biopsy) at the end of 8-week treatment.
  • CONCLUSION: We conclude that the solasodine glycoside cream Zycure is a safe therapy for basal cell carcinoma, with a cure rate of 66% at 8 weeks and 78% at 1 year follow-up.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Glycosides / administration & dosage. Skin Neoplasms / drug therapy. Solanaceous Alkaloids / administration & dosage
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Double-Blind Method. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Occlusive Dressings. Patient Dropouts. Pharmaceutical Vehicles / adverse effects. Pharmaceutical Vehicles / chemistry. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18173610.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glycosides; 0 / Pharmaceutical Vehicles; 0 / Solanaceous Alkaloids; L40Y453Y96 / solasodine
  •  go-up   go-down


99. Corsino PE, Davis BJ, Nørgaard PH, Parker NN, Law M, Dunn W, Law BK: Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. Neoplasia; 2008 Nov;10(11):1240-52
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.
  • The basal-like subtype of breast cancer is associated with invasiveness, high rates of postsurgical recurrence, and poor prognosis.
  • Aside from inactivation of the BRCA1 tumor-suppressor gene, little is known concerning the mechanisms that cause basal breast cancer or the mechanisms responsible for its invasiveness.
  • Here, we show that the heterogeneous mouse mammary tumor virus-cyclin D1-Cdk2 (MMTV-D1K2) transgenic mouse mammary tumors contain regions of spindle-shaped cells expressing both luminal and myoepithelial markers.
  • Cell lines cultured from these tumors exhibit the same luminal/myoepithelial mixed-lineage phenotype that is associated with human basal-like breast cancer and express a number of myoepithelial markers including cytokeratin 14, P-cadherin, alpha smooth muscle actin, and nestin.
  • The MMTV-D1K2 tumor-derived cell lines form highly invasive tumors when injected into mouse mammary glands.
  • The data suggest that the invasiveness of these cell lines results from a combination of factors including mislocalization of E-cadherin, beta-catenin, and p120(ctn) to the cytoplasm.
  • Nestin expression and E-cadherin mislocalization were also observed in human basal-like breast cancer cell lines, suggesting that these results are relevant to human tumors.
  • Together, these results suggest that abnormal Cdk2 activation may contribute to the formation of basal-like breast cancers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1999 Nov;31(5):965-6 [10580599.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1108-16 [16680155.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4373-80 [11106256.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):550-5 [11212248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Trends Genet. 2001 Oct;17(10):S18-22 [11585672.001]
  • [Cites] Oncogene. 2001 Nov 8;20(51):7514-23 [11709723.001]
  • [Cites] Breast Cancer Res. 2002;4(1):14-7 [11879554.001]
  • [Cites] Oncogene. 2002 Jul 11;21(30):4680-90 [12096344.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5097-107 [12140760.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7214-25 [12370811.001]
  • [Cites] J Cell Biol. 2003 Jun 23;161(6):1191-203 [12810698.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4425-33 [12853979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9958-61 [12904579.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):830-5 [14871808.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):95-104 [15082921.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3272-83 [15077190.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2269-78 [15161659.001]
  • [Cites] J Cell Biol. 1981 Dec;91(3 Pt 1):827-36 [7199047.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167-71 [2424019.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1791-7 [1923504.001]
  • [Cites] J Cell Biol. 1992 Mar;116(6):1381-93 [1541635.001]
  • [Cites] J Dairy Sci. 1992 Dec;75(12):3367-80 [1474204.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91 [16857790.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1217-26 [16938528.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1506-11 [16941011.001]
  • [Cites] Science. 2006 Dec 1;314(5804):1467-70 [17138902.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3149-56 [17055256.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R59 [17062128.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):501-10 [17234757.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] J Pathol. 2007 Mar;211(4):389-98 [17212342.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3135-44 [17409420.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9199-206 [17909025.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):479-91 [17996651.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):989-97 [18281472.001]
  • [Cites] J Mol Histol. 2008 Apr;39(2):193-9 [17960487.001]
  • [Cites] Neoplasia. 2008 May;10(5):450-61 [18472962.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 13;105(19):7040-5 [18443292.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5104-12 [18593909.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):59-67 [18598944.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R53 [18559090.001]
  • [Cites] Oncogene. 1993 Aug;8(8):2127-33 [8336939.001]
  • [Cites] Nature. 1994 Jun 23;369(6482):669-71 [8208295.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1996 Mar;32(3):149-58 [8925137.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1998 Jul;99(7):402-8 [9742518.001]
  • [Cites] Clin Cancer Res. 1995 Aug;1(8):889-97 [9816059.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2510-22 [15526158.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47688-98 [15355984.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):603-10 [15548370.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):6-10 [15665273.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):873-87 [15713751.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1321-8 [15990899.001]
  • [Cites] J Dairy Sci. 1992 Dec;75(12):3381-93 [1474205.001]
  • [Cites] Oncogene. 1993 Feb;8(2):279-88 [8426737.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10938-45 [16322241.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Mol Cell Biol Res Commun. 1999 Aug;2(2):77-85 [10542129.001]
  • (PMID = 18953433.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093651; United States / PHS HHS / / KG080510; United States / NCI NIH HHS / CA / R01-CA93651
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Intermediate Filament Proteins; 0 / Metalloproteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Phosphoproteins; 0 / Zyx protein, mouse; 0 / Zyxin; 0 / beta Catenin; 0 / delta catenin; 136601-57-5 / Cyclin D1; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  • [Other-IDs] NLM/ PMC2570600
  •  go-up   go-down


100. Chu CY, Cha ST, Chang CC, Hsiao CH, Tan CT, Lu YC, Jee SH, Kuo ML: Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells. Oncogene; 2007 Apr 12;26(17):2491-501
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells.
  • Basal cell carcinoma (BCC) is one of the most common skin neoplasms in humans and is usually characterized by local aggressiveness with little metastatic potential, although deep invasion, recurrence, and regional and distant metastases may occur.
  • We found that human BCC tissues and a BCC cell line had significant expression of CXCR4, which was higher in invasive than non-invasive BCC types.
  • We found that the CXCR4 ligand, stromal-cell-derived factor 1alpha (SDF-1alpha), directed BCC invasion and that this was mediated by time-dependent upregulation of mRNA expression and gelatinase activity of matrix metalloproteinase-13 (MMP-13).
  • [MeSH-major] Carcinoma, Basal Cell / enzymology. Carcinoma, Basal Cell / pathology. Chemokines, CXC / physiology. Matrix Metalloproteinase 13 / physiology
  • [MeSH-minor] Cell Line, Tumor. Chemokine CXCL12. Humans. Neoplasm Invasiveness. Receptors, CXCR4 / biosynthesis. Receptors, CXCR4 / genetics






Advertisement